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ABSTRACT
TUMOR INTERFERON SIGNALING INITIATES AND SUSTAINS A MULTIGENIC
RESISTANCE PROGRAM TO IMMUNE CHECKPOINT BLOCKADE
Joseph L. Benci
Andy J. Minn, M.D., Ph.D.

Therapeutic blockade of the CTLA4 and/or PD1 immune checkpoint pathways has
resulted in significant anti-tumor responses in broad variety of cancer types, but resistance
is common. Using mouse models of metastatic melanoma and breast cancer in
combination with CRISPR/Cas9 to selectively delete genes in our tumor cells, we
demonstrate that prolonged interferon signaling orchestrates PDL1-dependent and PDL1independent resistance to immune checkpoint blockade (ICB), and to combinations such
as radiation plus anti-CTLA4. Furthermore, we show that this interferon driven resistance
mechanism primarily occurs in ICB resistant tumors and not in ICB responsive tumors.
Persistent type II interferon signaling allows tumors to acquire STAT1-related epigenomic
changes and augments expression of interferon-stimulated genes and ligands for multiple
T cell inhibitory receptors. Both type I and II interferons maintain this resistance program.
Crippling the program genetically or pharmacologically interferes with multiple inhibitory
pathways, and expands distinct T cell populations with improved anti-tumor functions
despite expressing markers of severe exhaustion. Consequently, tumors resistant to multiagent ICB are rendered responsive to ICB monotherapy. Finally, we observe that
biomarkers for interferon-driven resistance associate with clinical progression after antiPD1 therapy. Thus, the duration of tumor interferon signaling augments adaptive
resistance and inhibition of the interferon response bypasses requirements for
combinatorial ICB therapies.
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CHAPTER 1: Introduction

Metastatic Disease is the Leading Cause of Cancer Related Mortality
Cancers can be classified as primary, located only in a single tissue, or metastatic,
having spread from that initial location to other nearby or even distant parts of the body.
With few exceptions, primary cancers are non-lethal and are easily managed by some
combination of radiation, chemotherapy, and/or surgical resection. It is the disseminated,
metastatic tumors that cause most cancer deaths. It is estimated that over 90% of all
cancer related deaths are due to metastatic not primary disease1. Among the 6 most
prevalent cancer types in the United States- Breast, Lung, Prostate, Colorectal, Bladder
and Melanoma – the average five-year survival drops from an average of 85% in primary
cancer to 16% in patients with metastatic disease2. Early detection is one of the most
important ways to improve survival by identifying a primary tumor before it has a chance
to metastasize.
Diagnostic technology has made significant advancements in the last thirty years.
Imaging modalities such as computed tomography (CT) and magnetic resonance imaging
(MRI) can slice patients into millimeter thick slices, allowing for increasingly early detection
of cancerous growths.

However, the enhanced diagnostic sensitivity also alters the

natural course of the disease3. Improved imaging resolution creates a lead-time bias
where survival statistics, such as the previously mentioned 5-year survival rate, increase
simply because of earlier detection, not because of any improvement in anti-cancer
therapies. Between 1950 and 1995, increases in five-year survivorship rates across
twenty cancer types, as reported by the National Cancer Institute’s surveillance,
epidemiology, and end results (SEER) program, had almost no correlation in changes with
cancer mortality4. This observation strongly suggests that improvements in five-year
survival were due to lead-time bias from increased early detection, not through
1

improvements in cancer therapies. Additionally, some of these lesions if left untreated
may never even develop into clinical disease at all, a concept known as overdiagnosis5,
thus improving survival statistics without changing disease outcome.
Although aggressive screening creates a lead time bias, the benefits of improved
screening for certain patient groups is undeniable. Women with the inherited BRCA2 gene
mutation have a 45% chance of developing breast cancer and an 11% chance of
developing ovarian cancer by age 706. In these high risk patients intensive screening
using both yearly mammogram and MRI to increase early detection increase ten-year
survival by 15% versus mammography alone7. Survival benefits with intensive screening
were also found in patients with a hereditary risk for pancreatic ductal adenocarcinoma.
In these patients the five year survival rate was 24%, nearly four times higher than patients
in the standard screening group8. In genetically predisposed individuals the benefits of
early and aggressive screening lead to significant survival benefits amongst multiple
cancer types.
One treatment modality which has significantly improved patient survival are a
class of drugs known as targeted therapies. Instead of being generally toxic to tumor cells
the way traditional chemotherapies and radiation are, targeted therapies interact with and
inhibit specific proteins within the tumor that are crucial for tumor proliferation and
survival9. Patients whose tumors rely on these druggable proteins derive significant
benefit from these therapies compared to traditional therapies. Targeted therapies against
BRAF driven melanoma, HER-2 positive breast cancer, and BCR-ABL driven leukemia,
as well as many other treatments significantly improve survival in patients whose tumors
depend on these proteins. However, many patient’s tumors do not have the required
targets for the drugs and even those who do can develop compensatory mutations
rendering the drugs ineffective. With the limited efficacy of exogenous therapies, many
showing only modest benefits against metastatic cancers, recent research has focused
2

on immunotherapy, marshalling the patient’s own immune system to fight the tumors has
led to significant and durable therapeutic responses.

Cancer Immunosurveillance
The idea that the immune system could detect and eliminate nascent tumors was
first proposed by Nobel Laureate Paul Ehrlich in 1909. Nearly fifty years later Prehn and
Main showed that carcinogen derived tumors could be rejected without any treatment
when transplanted into naive mice, however spontaneously occurring tumors could not be
rejected upon transplantation10, suggesting that these slow-to-develop spontaneous
tumors had undergone a different form of tumorigenesis than the carcinogen derived
tumors. These observations formed the root of the cancer immunosurveillance hypothesis
put forth by FM Burnet in 197011. The cancer immunosurveillance hypothesis proposed
that immune cells actively search for and eliminate transformed cells as they occurred
throughout the body, and that without this surveillance the rate of all cancer types would
be much higher at the population level than was observed. Under this theory, clinically
detectable tumors occurred when transformed cells escaped this immune elimination and
grew larger thus forming clinically detectable tumors. Though it would ultimately prove
correct, the cancer immunosurveillance hypothesis hit an early road block.
Nude mice are a common laboratory mouse strain harboring a genetic mutation
which causes them to have a nearly-absent thymus and which at the time of Burnet’s
paper were believed to completely lack T cells.

If the cancer immunosurveillance

hypothesis was correct, nude mice should develop spontaneous tumors at a much higher
frequency than wild-type mice and should be much more susceptible to carcinogen
induced tumors.

However, in a head-to-head comparison nude mice did not either

spontaneously or after exposure to carcinogens develop tumors at a higher frequency
than wild-type mice, suggesting the cancer immunosurveillance hypothesis was wrong 12.
This seemingly definitive experiment would shelve Burnet’s theory for nearly thirty years
3

before better mouse models would lead to renewed interest in the role of the immune
system in fighting cancer. Interferon gamma (IFN gamma) or interferon gamma receptor
knockout mice developed tumors faster and with greater frequency than wild-type
mice13,14. This suggested that IFN gamma was a central effector molecule in regulating
the anti-tumor response in mice, not coincidentally IFN gamma is known as a critical
mediator of T cell function15. Further evidence for the role of the immune system in
containing tumors came from the observation that mice lacking perforin, a protein used by
immune cells to kill target cells, develop B cell lymphomas at a high frequency16.
Transplanting these lymphomas into wild-type mice led to their rejection in a CD8+ T cell
dependent manner, consistent with Burnet’s original immunosurveillance hypothesis.
Finally, the development of the recombinant activating gene 1 (Rag1) knockout mice,
which have no T cells, provided a better host mouse to test the immunosurveillance
hypothesis.
Burnet was vindicated by the finding that in these Rag1 KO mice, a significant
fraction develop spontaneous lung and intestinal adenocarcinomas and they were also
significantly more susceptible to carcinogen induced tumors than wild-type mice17. Finally,
nearly 100 years after Paul Ehrlich first proposed that the immune system could detect
and eliminate tumors there was conclusive experimental proof this occurred in animals,
and that it was T cell dependent. Since then, the cancer immunosurveillance hypothesis
has been extensively studied in mice and there is evidence this process occurs in humans
as well. An analysis of 30 years of solid organ transplant recipients from the US Scientific
Registry of Transplant Recipients found a significantly increased risk of 32 different
malignancies in immunosuppressed transplant recipients compared to the general
population18. The increased risk of cancer among these immunosuppressed transplant
recipients mirrors the increased risk in Rag1 KO mice suggesting that the same
mechanisms of tumor surveillance occur in humans as well as mice.
4

Multiple Immune Populations Mediate Tumor Rejection
Consistent with Burnet’s hypothesis, the presence of CD8+ T cells in many tumor
types has been shown to correlate with better response to multiple therapeutic modalities.
An analysis of 109 stage II/III colon cancer patients found that amount of intratumoral
cytotoxic CD8+ T cells by histology correlated with improved overall and disease-free
survival in patients treated with either surgery alone or the combination of surgery and
chemotherapy19. Another study in colon cancer used RNA-sequencing to look for a
cytotoxic T cell signature also found a correlation between the strength of this signature
and a decreased incidence of recurrence post-surgery and improved overall survival20. A
meta-analysis of microarray data from over 2000 breast cancer patients found that in
tumors with high expression of immune metagenes there was decreased risk of
metastasis and increased overall survival21. In ovarian cancer, over half of all tumor
samples had T cells in the tumor, and patients with T cell rich tumors had a 5-year survival
rate that was seven times higher than patients without a strong T cell infiltrate22.

Despite

the focus of early pre-clinical researchers as well as many clinical papers on the ability of
the cytotoxic T cells to kill cancer cells, many immune cells play a role in the anti-tumor
response.
Natural killer (NK) cells can directly eliminate tumor cells that downregulate class
I MHC as a method of escaping T cell mediated immune surveillance23. Much like Rag1
KO mice developed tumors at an increased rate compared to wild-type mice, when dual
Rag KO/Perforin knockout mice were implanted with a colorectal cancer cell line, the
implanted tumors grew faster and developed an increased number of lung metastases
comparted to Rag single knockout mice24. This effect was NK cell dependent, showing
that NK cells can contain nascent tumors and metastases much the same way T cells can.
In mouse models of breast and lung cancer, NK cells were able to prolong tumor latency
by eliminating cycling tumor cells25. In vitro NK cells isolated from the blood of healthy
5

human donors were able to eliminate primary human melanoma cells treated with a subapoptotic dose of doxorubicin suggesting that in patients, chemotherapy can synergize
with immune cells to promote better tumor clearance26.
An additional immune subset that plays an important role in tumor killing is
dendritic cells (DCs). DCs play an important role in bridging the innate immune response
such as the non-specific killing of all MHC I low cells by NK cells and the highly specific
adaptive immune response mediated by T cells27. In vitro, DCs have been shown to
phagocytose apoptotic tumor cells and cross-present tumor antigens to prime CD8+ T cells
to better eliminate the tumor28. Similar to T cells, the presence of dendritic cells in the
tumor has been correlated with improved response to treatment and overall survival in
several cancer types29,30. There is currently a dendritic cell therapy, Sipuleucel-T, which
takes a patient’s own dendritic cells, expands them ex vivo in culture with a tumor protein,
and then infuses them back into the patient to prime an immune response. This therapy
has shown significant benefit in patients with metastatic prostate cancer31. However, not
all immune populations are anti-tumorigenic.
Macrophages can have either pro- or anti-tumor functions depending on their
polarization32. In the minority of cases macrophages correlate with better anti-tumor
response. In a study of 50 patients with non-small cell lung cancer the M1 macrophage
density in the tumor positively correlated with overall survival33. However, in many cancer
types patient prognosis is inversely correlated with tumor associated macrophage
density34,35. While the presence of macrophages in the tumor may be a double-edged
sword, the majority of immune cells in the tumor play a role in containing tumor growth
and improving response to therapy as evidenced by the increased tumor incidence in
immunocompromised mice and human patients13,17,18. Given the immune systems’ ability
to detect and eliminate tumors, why do otherwise immunocompetent patients develop
cancer at all?
6

Immune Checkpoints: A Double-Edged Sword
While the immune system plays a crucial role in protecting the host against
pathogens and cancer, over activation can cause autoimmunity which can be just as lifethreatening36. To protect against this, during T cell maturation cells that react to host
proteins are deleted to prevent autoimmunity in a process known as thymic selection37.
As a second line of defense against self-reactive T cells that escaped thymic selection,
and as a method of downregulating the immune response after an infection, there are also
inhibitory pathways hardwired into immune cells known as immune checkpoints38. One of
the most well studied immune checkpoints in the context of the anti-tumor response is
cytotoxic T lymphocyte-associated molecule-4 (CTLA4).
CTLA4 is expressed on T cells and competes with CD28 to bind CD80 and CD86
on antigen presenting cells39. CD28 binding with these two molecules provides a costimulatory signal which enhances T cell proliferation, cytokine production, and survival
while CTLA4 binding to either molecule provides an inhibitory signal40,41. This balance of
inhibitory and stimulatory signals balances the immune response and ensures that the T
cells do not become aberrantly activated in the absence of a foreign antigen, preventing
autoimmunity. The crucial role for CTLA4 in preventing autoimmunity is evidenced by the
fact that CTLA4 deficient mice develop fatal autoimmunity by 3-4 weeks of age42,43.
Consistent with the need for CD80/CD86 co-stimulation for T cell activation, this lethal
autoimmunity can be avoided by creating a CTLA4/CD80/CD86 triple knockout mouse44.
It was initially observed that there was a preferential expansion of CD4+ T cells in CTLA4
KO mice, and that depleting CD4+ T cells could delay the onset of autoimmunity however
depleting CD8s did not, suggesting that CTLA4 was a critical regulator of CD4+ T cell
function45. Later subsetting of the CD4+ T cell population showed that the CTLA4 was
mainly on regulatory CD4+ T cells (Tregs) which play a critical role in preventing
autoimmunity and inflammation46. Taken together, these results suggest that CTLA4 may
7

be turning off the T cell response that is so crucial in eliminating nascent tumors. This
was demonstrated over twenty years ago by Jim Allison who used a CTLA4 blocking
antibody to promote tumor regression in a mouse model of colon carcinoma47. This is one
of the first papers to show the benefits of blocking an immune checkpoint to promote tumor
clearance.
While CTLA4 was one of the first immune checkpoints discovered, it is not the only
one, nor is it the only one that has been shown to be important in cancer. Programmed
cell death protein 1 (PD1) is an inducible surface receptor expressed on activated CD4,
CD8, NK, and B cells48. When PD1 binds one of its ligands at the same time the T cell
receptor or B cell receptor (TCR or BCR) is engaged it transduces an inhibitory signal that
dephosphorylates the TCR or BCR blocking signal transduction. There are two well
characterized ligands for PD1, PD-L1 and PD-L249. PD-L1 is ubiquitously expressed
throughout the body and can be found on almost all lymphohematopoietic cells and in
most tissues of the body such as the heart, lungs, and kidneys50. PD-L2 is more restricted
in its expression and is primarily expressed in the liver. Like CTLA4, the PD1 pathway
functions to maintain peripheral tolerance and prevent aberrant killing of normal tissue
during an immune response.

PD-L1 is upregulated in the placenta which mediates

immune tolerance to the developing fetus, consistent with this inhibitory function, PD-L1
knockout mice have a lower fetal survival rate than wild-type mice51. Naïve dendritic cells
that present antigens to CD8+ T cells express high levels of PD-L1 to ensure that without
proper dendritic cell activation the T cells do not become activated, particularly against
self-antigens52. While not as drastic as the CTLA4 knockout mouse phenotype, PD1
knockout mice also develop late-onset autoimmunity and cardiomyopathy53. In addition
to preventing accidental immune activation against self-antigens and autoimmunity, the
PD1 pathway also serves to downregulate a correctly activated immune response after
infection to prevent host tissue damage. PD1 knockout mice clear an adenovirus infection
8

more quickly than wild-type mice but sustain more hepatocellular injury due to the
persistence of activated T cells after viral clearance54. However, too much PD1 signaling
can allow viral infections to persist. In HIV infected patients, higher PD1 expression on
virus specific T cells is associated with worse disease progression55. This double-edged
sword of PD1 signaling, with too much early in the immune response preventing effective
viral clearance, while not enough late in the response leading to tissue damage provides
some insight into how the PD1 pathway may allow tumors to escape elimination by the
immune system.
PD-L1 expression on murine tumor cell lines increased their resistance to T cell
mediated cytotoxicity and led to increased tumor growth in vivo56,57. PD-L1 expressed on
the tumor cells promotes T cell exhaustion, a functional state where the cell calls have
reduced proliferative and functional capacity including diminished cytokine production and
cytolytic activity crucial for killing tumor cells58. Tumors genetically engineered to express
soluble PD1 to bind up all the PD-L1 on the tumor surface were rejected at a significantly
greater frequency than tumors just expressing PD-L1 that was free to bind PD1 on the
immune cells59, suggesting that a PD1 or PD-L1 blocking antibody could be an effective
anti-cancer therapy.

In renal cancer patients, PD1 expression on tumor infiltrating

lymphocytes associates with worse outcome after radical nephrectomy than in patients
with PD1 low TILs60.

PD1 expression correlated with an immune suppressive

microenvironment and worse overall outcome in Hodgkin lymphoma as well61.

The

presence of immune checkpoints in multiple tumor types implies that tumors escape
immunosurveilance by taking advantage of these checkpoints to prevent elimination. As
Jim Allison’s work showed, using a blocking antibody against an immune checkpoint was
an effective way to unleash the immune system against an established tumor suggesting
this might be an effective clinical treatment47.

Immune Checkpoint Blockade as a Cancer Therapy
9

The watershed moment for cancer immunotherapy came in 2010 after a clinical
trial published in the New England Journal of Medicine showed significantly improved
survival in patients with metastatic melanoma treated with a CTLA4 blocking antibody
compared to the standard of care62. Not only was the median survival better in the patients
treated with anti-CTLA4 but about 20% completely cleared their tumor and remained
cancer free for the duration of the study follow-up. This study was closely followed by
another trial comparing the combination of anti-CTLA4 and dacarbazine to dacarbazine
alone. Dual treated patients had higher overall survival and longer progression-free
survival than patients treated with dacarbazine alone63. The results of this trial were so
striking that in March 2011 the Food and Drug Administration granted broad approval for
use of anti-CTLA4 in patients with metastatic melanoma either as a front-line therapy or
for refractory patients. Similar results were also observed in multiple other cancer types.
Anti-CTLA4 combined with chemotherapy in advanced non-small cell lung cancer
significantly improved overall survival versus chemotherapy alone64. In patients with
metastatic renal cancer anti-CTLA4 alone was sufficient to induce regression in 15% of
patients65.
While the clinical benefits of anti-CTLA4 in patients across a diverse array of
cancer types is undeniable, the therapy is not without its downsides. Nearly one-third of
patients experience severe side effects over the course of therapy, and the treatment can
take a long time to reduce the tumor burden, making it difficult to know whether patients
should remain on the drug or be switched to a different treatment66. While some patients
did derive significant benefit from anti-CTLA4 many did not, suggesting that resistance
could be occurring through additional immune checkpoints.
Some patients with metastatic melanoma who progressed on anti-CTLA4, were
able to get significant benefit from a clinical PD1 blocking antibody, suggesting this may
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be one mechanism of resistance to anti-CTLA4 blockade67. Even in patients who had not
received previous treatment with anti-CTLA4, anti-PD1 lead to a significant improvement
in overall survival versus dacarbazine68. Responses to PD1 blockade were dramatic in
several other cancer types as well including non-small cell lung cancer and Hodgkin
lymphoma69,70. Blocking PD-L1, the ligand for PD1 showed dramatic responses in several
cancer types including metastatic bladder cancer71. A head-to-head trial of anti-CTLA4
and anti-PD1 in advanced metastatic melanoma showed PD1 blockade led to better
overall survival and progression free survival than anti-CTLA472. Since PD1 and CTLA4
are distinct immune checkpoints, blocking both simultaneously could lead to better
response than either one as a single agent therapy. In one of the first trials looking at the
combination of anti-CTLA4 and anti-PD1 in metastatic melanoma, 65% percent of patients
responded, with over half having more than an 80% reduction in total tumor burden73.
However, as the observations from CTLA4 and PD1 knockout mice would suggest,
blocking multiple immune checkpoints can lead to serious side effects. In another trial,
over 60% of patients derived some benefit from the combination therapy however several
died from treatment related toxicities74.

Combining a single immunotherapy with an

additional therapy such as radiation is one potential avenue to maintain strong anti-tumor
responses while reducing toxicity.
Radiation can synergize with the immune system in several ways including
promoting cytokine release, improving antigen presentation, and promoting a more antitumorigenic microenvironment75. Several preclinical reports indicate that radiation at a
single tumor site could synergize with immune checkpoint blockade to promote tumor
clearance even in unirradiated metastatic tumors, a phenomenon known as the abscopal
effect76,77. There have also been several anecdotal clinical cases where patients treated
with immune checkpoint blockade received radiation at a single tumor site and
experienced dramatic reductions in their total tumor burden78. There are currently over
11

100 clinical trials looking at the combination of radiation and immunotherapy. In addition
to anti-CTLA4 and anti-PD1 there are also several other immune checkpoint antibodies in
various stages of development.
Lymphocyte-activation gene 3 (LAG3) is expressed on T cells and binds to class
II MHC to downregulate the T cell response. Mice lacking LAG3 have nearly twice the
number of T cells as wild-type mice79. LAG3 synergizes with PD1 to prevent autoimmunity
in mice suggesting it could also provide a non-redundant inhibitory signal that allows
tumors to escape PD1 therapy80. Bristol-Meyers Squibb is currently looking at a LAG3
blocking antibody for use in solid tumors with or without the addition of anti-PD1
(NCT01968109). TIM3 functions in a similar way to LAG3, it is expressed on activated
CD8+ T cells and when it binds its ligand, galectin-9, it triggers cell death pathways in the
T cells81. In a murine model of colon carcinoma, almost half the intratumoral T cells were
TIM3/PD1 double positive and adding an anti-TIM3 blocking antibody to anti-PDL1
significantly boosted the anti-tumor response82. A comparison of PD1 and TIM3 blocking
antibodies is currently accruing patients (NCT02817633). T-cell immunoreceptor with Ig
and ITIM domains (TIGIT) is highly expressed on CD8 T cells in both humans and mice
with cancer83,84.

Treatment with a TIGIT blocking antibody led to significant tumor

reduction in mice83. A trial evaluating a TIGIT blocking antibody as a single agent or in
combination with anti-PD1 is currently recruiting participants (NCT02794571).
It is unclear how effective these combination therapies will be in human cancers
which display significantly more heterogeneity than mouse models and as with the
combination of anti-CTLA4 and anti-PD1, dosing may be limited by treatment associated
toxicities. A CD28 agonistic antibody designed to over-activate T cells at the priming stage
put all 6 of the healthy human volunteers in the intensive care unit for several weeks,
demonstrating how dangerous tampering with these immune checkpoints can be85. Given
these risks, understanding which patients will benefit from a certain blocking antibody and
12

which will not is of critical importance. Additionally, many patients who initially respond to
anti-CTLA4, anti-PD1, or combination therapies eventually relapse and understanding
these mechanisms of resistance will allow for the development of additional therapies to
better improve response.

Innate Resistance to Immunotherapy
Resistance to immunotherapy can occur through certain intrinsic characteristics of
the tumor cells that make them more resistant to immune mediated clearance, this is
known as innate resistance38. One way tumors can escape T cell mediated killing after
anti-CTLA4 or anti-PD1 therapy is by having a low neo-antigen burden. T cells recognize
small fragments of peptides known as antigens86. Each T cell expresses a unique T-cell
receptor (TCR) on the cell surface which recognizes a unique antigen presented in a major
histocompatibility complex (MHC) by the host cell. CD8+ T cells recognize 8-10 amino
acid long peptides presented by Class I MHC while CD4+ T cells recognize longer peptides
presented by class II MHC. Class I MHC is robustly expressed on all nucleated cells in
the body while class II is more restricted, mainly found on certain immune subsets.
Interaction between the TCR and the peptide/MHC complex along with co-stimulatory
signals causes the T cell to become activated. After activation, CD8+ T cells then divide
and produce cytotoxic proteins such as perforin and granzyme to enable killing of cells
expressing the peptide their TCR recognizes.
One of the hallmarks of cancer is genomic instability and subsequent DNA
mutations as a result of this instability87. The mutational burden is not equal across cancer
types, with melanoma and various subtypes of lung cancer being very highly mutated in
patient samples, while thyroid and prostate cancer show relatively low levels of
mutations88. These mutations can create antigens which are not normally present in the
host, known as neoantigens, which would be good targets for T cells activated by immune
checkpoint blockade to recognize and eliminate 89. Consistent with this, cancers that are
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the most highly mutated also have the greatest proportion of patients that derive some
benefit from treatment with anti-PD190. A high neo-antigen signature predicted clinical
response to anti-CTLA4 in patients with metastatic melanoma, and peptides of these
predicted neo-antigens were able to activate T cells isolated from the patients in vitro,
suggesting that these were the tumor specific antigens the patients’ T cells were reacting
against91. In 9 out of 10 patients with metastatic gastrointestinal cancer, T cells isolated
from a tumor biopsy recognized one to three predicted neo-antigens from the patient’s
tumor92. Neo-antigen burden also predicted patient response to anti-CTLA4 and antiPDL1 in non-small cell lung cancer where the mutational load is frequently very high93.
However, in patients with low neo-antigen burdens, there may be little for the T cells to
react to and therefore little tumor killing after immune checkpoint blockade. In a mouse
model of pancreatic cancer with no strong neo-antigens, the tumor elicited very weak
immune activation after implantation, but one synthetically engineered to express a strong
neo-antigen was rejected upon implantation in a T cell dependent manner94.
Since T cells rely on tumors expressing these antigens to detect and eliminate
them, one way tumors can escape elimination is through the process of immunoediting.
The immunoediting hypothesis is a modern version of Paul Ehrlich’s work divided into
three distinct stages of tumor growth, elimination, equilibrium, and escape95.

In the

elimination phase, transformed cells are spontaneously recognized and destroyed by the
innate and adaptive immune systems. If the cells grow quickly enough, they enter the
equilibrium phase where tumor cells are constantly being eliminated by the immune
system but regenerate fast enough to avoid complete tumor clearance. Finally, in the
escape phase the tumor escapes elimination by the immune system and grows into a
clinically detectable tumor. While difficult to study in humans, this process has been well
characterized in mouse models. Tumors from immunocompetent mice still grown when
transplanted to other immunocompetent mice, however tumors from immune deficient
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mice are rejected upon transplant into an immune competent mouse17. This suggests that
tumors developing in the presence of a competent immune system undergo changes that
make them resistant to further immune killing while tumors from immune deficient mice do
not. These immunoediting changes can occur due to selective pressure from T cells or
from components of the innate immune system such as NK cells96-98. In patients, the
average tumor loses between 7 and 18 neoantigens after immune checkpoint blockade,
suggesting that immunoediting occurs in humans as well99. Additionally, the adoptive
transfer of antigen specific CD8+ T cells causes these antigens to be selectively lost in
relapsed patient tumors either through reduced gene expression or loss of the mutant
allele100.
A related way cancers can escape elimination by the immune system is through
the downregulation of MHC. Even if the tumor contains several neo-antigens, without the
ability to present these antigens to the T cells the tumor can avoid T cell mediated killing.
Several recent clinical reports looking at metastatic melanoma patients who progressed
on either anti-CTLA4 or anti-PD1 found an enrichment for mutations that led to
downregulation of antigen processing and presentation suggesting this is an alternative
way for antigen rich tumors to escape elimination101,102. In addition to making it more
difficult for activated T cells to recognize and eliminate the tumor through antigen loss or
MHC downregulation, tumor cells have also co-opted the immune checkpoint signaling
pathways to downregulate the immune response.
As previously discussed, PD1 is expressed on activated T cells and engagement
with its ligands PD-L1 or PD-L2 can lead to T cell anergy and deletion. Many common
oncogenes including EGFR, MYC, and AKT-mTOR that drive tumorigenesis can also drive
PD-L1 expression in both human and animal cancer cell lines90,103-105. Additionally, PDL1
can signal into the tumor to increase glycolysis, leading to a defective T cell response
through nutritional deprivation106. However, some studies of the relationship between
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these oncogenes and PD-L1 expression have failed to find this correlation in studies of
squamous cell carcinoma as well as lung adenocarcinoma patients107,108. Regardless of
whether PD-L1 expression can be driven by oncogenes or through some other
mechanism, high levels of PD-L1 on the tumor has been observed to promote resistance
to anti-CTLA4 blockade. In metastatic melanoma patients treated with the combination of
radiation and anti-CTLA4, high PD-L1 levels predicted faster relapse109. In another study
of metastatic melanoma patients treated with anti-CTLA4 monotherapy, no correlation
between tumor PD-L1 expression and anti-CTLA4 response was found110. However, for
patients in this study who progressed on anti-CTLA4 monotherapy, PD-L1 status was
predictive of response to PD1 blockade. It should be noted that comparing clinical trials
can be challenging as there is no set standard of what intensity of PD-L1 staining
constitutes a positive or high patient. The increased PD-L1 expression in these patients
and cell lines occurs through tumor intrinsic mechanisms and is independent of what is
happening in the tumor microenvironment, however resistance can also arise though an
adaptive response to signals from the tumor microenvironment, principally interferon.

Interferon Signaling and Cancer
Interferon signaling was first discovered in the context of the anti-viral response.
Interferon was released by chick membranes upon exposure to heat inactivated virus and
the it helped make the cells more resistant to subsequent live virus infection111. Production
of interferon and subsequent downstream interferon signaling is induced by components
of the innate immune system through the toll-like receptors and other pattern recognition
receptors, which function as molecular sensors of damage or pathogen associated
molecular patterns such as viral DNA or RNA. There are two main types of interferons
(IFNs), type I which includes IFN alpha and IFN beta, and type II which has only a single
protein IFN gamma. There are multiple isoforms of IFN alpha, humans have 14 and mice
have 13 all of which have a highly conserved structure and signal through a common
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receptor, suggesting they were evolutionarily conserved for specific functions112.
Microarray analysis of genes upregulated after treatment with IFN alpha, beta, or gamma
shows that each IFN type upregulates genes related to a diverse array of biological
functions113. Some genes were induced by all three types of interferon while others were
unique to only one. These effects were also temporal, with over 2000 genes going up and
back down at different times post-interferon exposure, suggesting a complex regulatory
mechanism of interferon signaling114.
Interferons signal into the cell by binding to their respective receptor on the cell
surface which causes rearrangement and dimerization of the two receptor subunits
followed by autophosphorylation of the intracellular janus kinases. The interferon alpha
receptor (IFNAR) is composed of two subunits IFNAR1 and IFNAR 2 which are associated
with tyrosine kinase 2 (TYK2) and janus kinase 1 (JAK1) respectively. IFNAR binds to all
Type I IFNs115. After binding, JAK1 phosphorylates signal transducer and activator of
transcription 1 (STAT1) which then forms a STAT1-STAT2-IRF9 heterotrimer.

This

complex translocates into the nucleus and binds to IFN stimulated response elements in
the DNA to initiate gene transcription. Like IFNAR, the interferon gamma receptor (IFNGR)
is composed of two subunits IFNGR1 and IFNGR2 which associate with JAK1 and JAK2
respectively.

When IFN gamma binds to IFNGR the JAKs phosphorylate STAT1, a

STAT1/STAT1 homodimer forms which goes to the nucleus and binds gamma-activated
sequences in the promoters of certain genes to initiate transcription112.
The genes which are transcribed after IFN signaling are collectively known as the
interferon stimulated genes (ISGs).

These genes and their upstream pathway

components are often expressed at low baseline levels, but their expression is
dramatically enhanced by IFN signaling. This allows the cells to respond quickly after a
pathogen or damage signal is detected. After IFN signaling is activated, the cells enter a
de-sensitization state that can last for several days116.
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This downregulation occurs

through concurrent downregulation of the IFNRs by receptor mediated endocytosis as well
as dephosphorylation of JAKs and STAT1117. Using cyclohexamide to inhibit new protein
synthesis after treating cells with IFN lengthens the amount of time ISGs are transcribed,
suggesting one part of IFN signaling is creating the proteins necessary to downregulate
the response116. One of the most important negative regulators that is transcribed this
way is the ubiquitin-specific peptidase 18 (USP18) which binds to the intracellular domain
of the IFNRs and causes a conformational change which prevents further IFNs from
binding118. These negative regulatory pathways are critical because they allow the cells
to recover and prevents a positive feedback loop where transcription of the ISGs drives
continuous ISG expression which can lead to autoimmunity119.
In addition to playing important roles in anti-viral defense and damage sensing,
interferon signaling also plays several crucial roles in regulating the function of immune
cells. Type I IFN is required for the optimal cytotoxic functions of NK cells in clearing a
murine CMV infection120. During the anti-viral response, type I IFN also inhibits the
proliferation of regulatory T cells and helps the proliferation of helper T cells allowing for
improved viral clearance in mice121,122. IFN alpha produced by dendritic cells (DCs) is
important in blocking myeloid derived suppressor cells (MDSCs) in vitro and treating mice
with recombinant IFN alpha blocks MDSC function in vivo123. Interferon signaling also
plays an important role in allowing the immune system to better attack and clear tumors.
IFN beta improves dendritic cell cross-priming after tumor implantation which induces
better T cell activation and improved tumor clearance124-126. Type II IFN also plays an
important role in anti-tumor immune activation, as IFN gamma polarizes macrophages to
the M1 state which gives them better tumor killing capabilities127. Besides activating the
immune system, interferons also can function directly as anti-tumorigenic agents.
Both type I and type II IFN can directly inhibit tumor growth. IFN gamma slows
proliferation and increases apoptosis in both immortalized human melanoma cell lines as
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well as primary patient samples of head and neck cancer128,129. These effects are dose
dependent, as low levels of IFN gamma leads to STAT1 activation and ISG transduction
in vitro; however higher doses induce a growth delay and even death130. Type I IFN can
also affect all phases of the cell cycle, blocking G1 entry, or lengthening the G2/M
checkpoint in both immortalized and primary cells131. Besides directly inhibiting tumor
growth or inducing cell death, tumor-intrinsic interferon signaling can also indirectly
improve tumor clearance. Both types of interferon can upregulate class I MHC expression
across a diverse array of tumor types132,133. As previously discussed, this leads to better
recognition of the tumor and neo-antigens by CD8+ T cells and therefore improved tumor
clearance.
Interferon therapy is currently being used clinically to treat some types of cancer,
however the results have been mixed. Recombinant interferon alpha is currently approved
for the treatment of melanoma, Kaposi sarcoma, and several hematological malignancies.
High risk melanoma patients who got IFN therapy had longer relapse free survival,
however a trial in colorectal cancer did not show any benefit134,135. Recombinant interferon
gamma did not make it out of the clinical trial phase as some trial patients derived no
benefit and others actually had to be stopped early because the patients receiving
recombinant gamma were performing worse than controls136,137. Despite well-defined
roles for both types of interferon in controlling tumor growth and promoting immune
mediated tumor clearance, clinical results were mixed. This suggests that in addition to
these anti-tumorigenic properties, interferons also may increase resistance to treatment
or immune mediated tumor rejection.

Interferon Mediated Adaptive Resistance to Immunotherapy
Despite the immune system’s strong dependence on interferon signaling for proper
activation and effector function in response to infections and tumors, acute interferon
signaling can also have deleterious effects. Mice lacking IFNAR have lower bacterial
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loads during listeria infections and blocking type I IFN inhibited tuberculin bacterial growth
in infected macrophages138,139.
In tumors, IFN signaling can also promote resistance to therapy. A subset of
interferon stimulated genes (ISGs) known as the interferon-related DNA damage
resistance signature (IRDS) predicted poor response to chemotherapy and loss of regional
control after radiation in breast cancer patients140. Expression of IFN and STAT1 mediated
genes also predicted poor overall survival in glioblastoma multiforme141. Only a subset of
less than 30 ISGs were consistently expressed in these therapy resistant tumors. One
recent study implicated IFN signaling in resistance to anti-PD1 blockade, with ISGs slightly
enriched in the non-responding patients142. Interferon driven resistance is considered
adaptive resistance as it occurs in the tumor as a response to some initial challenge such
as radiation or immune infiltration38. A major component of this adaptive resistance is the
upregulation of PD-L1, the ligand for PD1, on the tumor cells. Interferon gamma produced
by lymphocytes induced tumor PD-L1 and promoted progression in acute myeloid
leukemia and ovarian cancer143,144. Interferon driven expression of PD-L1 in tumor cells
has also been observed in several pre-clinical animal models109,145. In addition to driving
PD-L1 expression, IFNs can also promote the expression of other genes that promote
resistance to immune cell mediated killing. Another well characterized inhibitory ligand
that is induced in the tumor after exposure to interferon is indoleamine-2,3-dioxygenase
(IDO). IDO is upregulated in the tumor after exposure to IFN gamma produced by CD8 +
T cells and functions to deactivate the T cells145. In addition to driving the expression of
genes that downregulate the immune response, IFNs can also promote metastasis.
Murine melanoma and breast cancer cells treated with IFN gamma in vitro displayed
decreased growth, however when injected into mice they displayed a lung colonizing
phenotype146,147. In addition to these acute effects of interferon on both the immune
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system and the tumor, chronic exposure to interferon can also have deleterious effects on
both compartments.
In mice infected with an incurable strain of LCMV, CD8+ T cells express an
elevated interferon signature, and treating with a type I IFN blocking antibody after the
infection had reached this chronic state increased immune activation, decreased
expression of inhibitory molecules, and improved viral clearance148,149. Blocking IFN beta
but not IFN alpha controls the infection, demonstrating the unique roles of each IFN
subtype150. The temporal importance of interferon signaling can also be seen in simian
immunodeficiency virus infected monkeys. Type I IFN treatment initially helps control viral
load, however if treatment is continued the infection becomes worse151. There were also
different effects depending on which IFN alpha was used. Less well studied is the role of
chronic interferon signaling on the tumor. In vitro exposure of fibroblasts to low levels of
IFN upregulates ISGs with no increase in pro-apoptotic or anti-proliferative ISGs114. In
cancer cells, chronic exposure to IFN beta drives expression of the IRDS genes and
promotes resistance to radiation and chemotherapies similar to what has been previously
observed in patients140,152.

Given these observations it is possible that during

tumorigenesis or after treatment with immune checkpoint blockade, chronic interferon
signaling in the tumor promotes these types of changes leading to treatment resistance
and tumor relapse.

Dissertation Objectives
Interferon signaling regulates a diverse array of cell processes both in normal and
malignant cells. High levels of interferon signaling within tumors has been shown to
predict poor prognosis to chemotherapy and radiation therapy, however the role of
interferon signaling in regulating resistance to immune checkpoint blockade remains
poorly understood. Additionally, PD-L1 expression has been shown to correlate with
resistance to immune checkpoint blockade, specifically combination treatments involving
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anti-CTLA4. PD-L1 staining has been found on both the tumor cells as well as tumor
infiltrating lymphocytes, however, the relative importance of PD-L1 on each of these
populations remains poorly understood.

The goal of this thesis is to address how

interferon signaling can mediate resistance to immune checkpoint blockade through the
following specific aims:
1. Study the contribution of immune and tumor PD-L1 in resistance to ICB
We hypothesize that both tumor and immune PD-L1 are capable of mediating
suppression of the immune response after ICB. To study this in vivo we utilized the
CRISPR/Cas9 system to create PD-L1 knockout cell lines. We found that in our primary
cell lines tumor PD-L1 was the significant driver of resistance. 80% of mice with PD-L1
KO tumors had complete tumor clearance after treatment with anti-CTLA4+RT. In our
resistant tumors, the response was less dramatic with only 35% of mice clearing their
tumors.
Utilizing flow cytometry for we identified F4/80+ macrophages as an abundant and
PD-L1 high immune subtype. Depleting tumor associated macrophages with an antiCSF1R antibody also improved response.

We also showed a differential effect of

knocking out STAT1, a central mediator of interferon signaling, in our primary and resistant
tumor lines. These results suggest that additional PD-L1 independent interferon mediated
resistance mechanisms may be present in some tumor types but not others.
2. Study the role of chronic interferon signaling in resistance to ICB
Given our divergent results in the STAT1 KO tumors we hypothesized that chronic
interferon exposure in our relapse cell lines caused changes that made them more
resistant to ICB. To test this, we treated parental B16 cells in vitro for three weeks with
low levels of interferon; when injected into mice the tumors were significantly more
resistant than untreated cells. Using ATAC-Seq we identified chromatin remodeling at
STAT1 binding sites that had occurred because of this chronic interferon exposure. In our
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resistant cell lines knocking out either type I or type II IFN receptors dramatically
resensitized the tumors to single agent ICB.
Concomitant with this improved response we observed a marked expansion of
deeply exhausted CD8+ T cells after ICB in the interferon receptor knockout tumors. This
suggests that knocking out the interferon receptors, and therefore interferon driven
inhibitory ligands on the tumor, allows for the expansion of exhausted CD8+ T cells
expressing the receptors for those inhibitory ligands. This improved response was also
recapitulated in wild-type tumors treated with a clinically available JAK inhibitor.
Taken together, these results suggest that PD-L1 is a primary resistance
mechanism which can be overcome with a PD1 or PD-L1 blocking antibody. However, in
relapsed tumors, or tumors which have already been exposed to chronic interferon, PD1
blockade alone is insufficient to promote tumor clearance. In these tumors, blocking
interferon signaling through CRISPR knockout of the interferon receptors, or chemical
inhibition of interferon signaling with a JAK inhibitor are necessary to restore sensitivity to
ICB.
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Chapter 2

Introduction
Immune checkpoint blockade (ICB) has led to unprecedented clinical responses in
patients with a variety of metastatic cancers62,153,154. Unfortunately, many patients still
progress on these treatments. Optimal clinical response will likely require combinations
of different ICB antibodies as well as the addition of other treatments. Several recent
clinical reports have indicated that radiation (RT) may be one such additional treatment,
as several patients receiving radiation and ICB had complete tumor clearance, including
in their unirradiated tumors155-157. We have previously reported that radiation synergizes
with ICB to expand and reshape the T cell receptor (TCR) repertoire, both in the irradiated
tumor as well as in the unirradiated tumor and in the periphery109. The new TCR repertoire
likely favors tumor-specific T cells as response was dramatically improved in mice who
received the combination of anti-CTLA4+RT versus either treatment as a single agent.
Radiation has also been reported to alter peptide presentation which could further assist
in the expansion of tumor specific T cells158. However, despite impressive initial responses
and even complete tumor clearance and memory in a subset of the mice, many others
were still resistant.
When the unirradiated, “abscopal,” tumors from some of these mice were isolated
and transplanted into naïve mice they were extremely resistant to the combination of antiCTLA4+RT. RNA-sequencing on untreated bulk parental or relapsed tumors identified
PD-L1 as one of the most upregulated genes in the resistant tumors109. This is consistent
with other reports that the PD1/PDL1 pathway mediates resistance to ICBs such as antiCTLA4 and anti-CD40159,160. In our mouse model when a PD-L1 blocking antibody was
combined with anti-CTLA4+RT in the parental melanoma tumors, we saw dramatically
improved overall survival implicating PD-L1 as a mechanism for resistance to the
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combination of anti-CTLA4+RT. Based on these results we hypothesize that PD-L1 is a
dominant resistance mechanism in relapse tumors and blocking it will lead to even more
dramatic responses than in the parental tumors.

Results
As PD-L1 can be expressed by both tumor cells and immune cells50,161, to
specifically evaluate the contribution of tumor PD-L1 to resistance we utilized the
CRISPR/Cas9 system to ablate PD-L1 expression in the tumor cells162. We confirmed the
successful knockout of PD-L1 in both the parental murine melanoma cell line B16-F10
(B16) as well as the isolated late relapse tumor that was resistant to the combination of
anti-CTLA4+RT, called 499, using flow cytometry (Figure 1A, 1B). As interferon gamma
(IFNg) treatment was a known way to further increase PD-L1 in these cells145, in addition
to untreated cells we also stimulated the cells with 100 ng/mL of IFNg for 16 hours to
induce maximum PD-L1 expression prior to flow staining. The PD-L1 null cell lines
generated from B16 or 499 were termed B16 PDL1 KO and 499 PDL1 KO respectively.
When B16 PDL1 KOs were injected into mice and treated with anti-CTLA4+RT the
response was dramatic, with nearly 80% of the mice completely clearing their tumors
(Figure 1C). 499 PDL1 KOs also displayed increased survival over 499; however, PDL1
KO in this cell line did not lead to as dramatic of a response, with only one-third of mice
completely clearing their tumors (Figure 1D).

This result was surprising given the

enhanced PD-L1 expression in bulk 499 tumors compared to B16 by RNA-seq109. This
difference in survival after PD-L1 KO was also observed in a murine model of breast
cancer. Parental breast cancer cell line TSA, and an isolated relapse tumor after treatment
with anti-CTLA4+RT, 237, displayed similar response kinetics after PD-L1 KO (Figure 1
E-H). These observations suggest that the increased PD-L1 by RNA-seq as well as the
lower response to anti-CTLA4+RT in the relapse PDL1 KO tumor lines could be due to
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the increased expression of PD-L1 on other cells in the tumor microenvironment, not the
tumor cells themselves.
To interrogate whether PD-L1 expressed in the tumor microenvironment could be
contributing to resistance to anti-CTLA4+RT in our PDL1 KO tumors, we looked at PD-L1
expression in untreated tumors by flow cytometry. In both B16 and 499 tumors there was
significant expression of PD-L1 by CD45+ tumor infiltrating lymphocytes (TILs) (Figure 2A).
As previously reported109, there was a difference in PD-L1 staining intensity on the tumor,
however no difference in PD-L1 positivity was observed on the TILs (Figure 2B). Given
the expression of PD-L1 on these immune cells, and our previous success augmenting
response to anti-CTLA4+RT in parental B16 and 499 tumors by adding a PD-L1 blocking
antibody109, we decided to add a PD-L1 blocking antibody to mice bearing PDL1 KO
tumors. Mice injected with B16 PD-L1 KO tumors treated with the triple therapy of antiCTLA4+anti-PDL1+RT had no discernable benefit over mice treated with just antiCTLA4+RT (Figure 2C). This lack of improved response may be due to the relative
unimportance of PD-L1 positive TILs in mediating resistance in this model, or because
there is such a small window for improvement that the study was underpowered to detect
a statistically significant result. However, 499 PDL1 KOs treated with triple therapy had a
dramatically improved response, with close to 60% of the mice completely clearing their
tumors, suggesting that PD-L1 expression on TILs can mediate resistance to ICB in this
model (Figure 2D).
Further subsetting of the TILs into specific immune lineages implicated
macrophages as the likely driver of this PD-L1 mediated resistance. They are both
abundant in the tumor, comprising roughly 20% of the total TILs, and highly express PDL1 relative to other immune lineages in 499 tumors (Figure 3A). Several recent clinical
reports have found PD-L1 high macrophages in primary and metastatic patient
samples163,164, so we wanted to evaluate the possible role of these macrophages in
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mediating resistance to anti-CTLA4+RT. Macrophages have been found to play both proand anti-tumorigenic roles depending on their polarization165. M1 polarized macrophages
are considered to have anti-tumor functions while M2 polarized macrophages are
generally considered to be pro-tumorigenic. Utilizing a validated flow cytometry panel for
characterizing macrophage polarization166, we evaluated the macrophages in untreated
499 tumors.

We found that the tumor associated macrophages (TAMs) were

predominantly the M2 phenotype and that M2 TAMs expressed significantly more PD-L1
than M1 TAMs (Figure 3B, 3C). Given these findings we hypothesized that macrophages
were likely helping suppress the anti-tumor response after anti-CTLA4+RT. The major
survival cytokine for macrophages colony-stimulating factor 1 (CSF-1)167. To deplete
tumor-associated macrophages we utilized a blocking antibody to the receptor for CSF-1
(CSF-1R) which was effective in depleting over 90% of the intratumoral macrophages
(Figure 3D).

Combining anti-CSF-1R with anti-CTLA4+RT in parental 499 tumors

significantly improved overall survival (Figure 3E). Taken together with the anti-PDL1
blocking antibody results, this suggests that PD-L1 on macrophages plays an
immunosuppressive role leading to worse response after anti-CTLA4+RT.
To test the clinical significance of these findings we utilized previously published
results from a clinical trial of anti-CTLA4+RT in metastatic melanoma109. We modeled
overall survival as a function of PD-L1 surface staining and positivity on both the tumor
cells as well as macrophages.

Both tumor and macrophage PD-L1 independently

contribute to survival, with higher PD-L1 intensity scores on both predicting for worse
outcome (Figure 3F).

Similar to the 499 PDL1 KO treated with anti-CTLA4+anti-

PDL1+RT, patients on the trial with low PD-L1 on both tumor and macrophages had
improved survival but a significant fraction still had a 40-50% risk for death, implicating the
existence of PD-L1 independent resistance mechanisms to anti-CTLA4+RT in patients as
well as in mouse models (Figure 3G).
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Similar to proposed models of ICB resistance168, the PD-L1 independent
resistance mechanism observed in our mouse model of melanoma is tumor intrinsic. JB2
is a late relapse cell line isolated from a 499 PDL1 KO tumor treated with anti-CTLA4+antiPDL1+RT (Figure 4A). These JB2 cells were still PD-L1 null, indicating resistance was
occurring through a PD-L1 independent mechanism (Figure 4B). When JB2s were reimplanted into naïve mice and treated with anti-CTLA4+RT they were as resistant as
parental 499 tumors despite expressing no PD-L1 (Figure 4C).

PD-L1 independent

resistance was also observed in our clinical trial; several patients who progressed on the
combination of anti-CTLA4+RT went on to receive anti-PD1 and then experienced further
disease progression regardless of the PD-L1 status of their tumor cells and/or
macrophages (Figure 4D).
We have previously observed elevated levels of PD-L1 in resistant 499 tumors
comparted to B16 both by RNA-seq and flow cytometry (Figure 2A)109. Given that PD-L1
has been reported to be an interferon stimulated gene (ISG)145, and high ISGs have been
reported to correlate with resistance to multiple therapies across multiple cancer types140,
we hypothesize differential interferon signaling could be regulating the resistance in the
relapsed cell lines 237, 499, and JB2. RNA-seq on untreated bulk B16 and 499 tumors
showed comparable levels of many different types of interferon as well as their receptors
between the two tumor types (Figure 5A). It has also been reported that radiation can
induce both type I and type II IFNs within the tumor169,170, suggesting that treatment could
be causing changes in interferon expression. In mice bearing B16 tumors, after treatment
with anti-CTLA4+RT IFN-gamma but not Type I IFNs are detectable in the blood one week
after treatment (Figure 5B). Other inhibitory mechanisms including IDO and HVEM are
also inducible by IFNg109,145, so it is possible these could be getting induced post-antiCTLA4+RT and mediating PD-L1 independent resistance.
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STAT1 is an essential downstream signaling molecule and transcription factor for
both type I and type II IFN signaling so we decided to CRISPR it out in both parental and
ICB resistant tumors to evaluate the role of IFN induced resistance in our models (Figure
5C and 5D). While knocking out PD-L1 improved response in both parental and resistant
tumors, we observed strikingly divergent phenotypes in parental and resistant tumors after
STAT1 KO. In both parental B16 melanoma, and TSA breast cancer tumors, STAT1 KO
led to worse response to anti-CTLA4+RT than in wild-type tumors (Figure 5E).
Conversely, in the resistant 499 melanoma and 237 breast cancer tumors, STAT1 KO led
to increased response after anti-CTLA4+RT (Figure 5F). This divergent response after
anti-CTLA4+RT was also observed after treatment with anti-PD1 monotherapy, with 499
STAT1 KOs doing better than wild-type while B16 STAT1 KOs had no improvement
(Figure 5G and 5H). Consistent with our observations in B16 and TSA tumors, loss of IFN
signaling and/or JAK/STAT signaling has recently been reported as a resistance
mechanism to ICB101,102. However, it is unclear why STAT1 KO has such divergent
functions in parental versus relapse tumors.
Knocking out PD-L1 in addition to STAT1 in parental B16 tumors improves
response after anti-CTLA4+RT back to wild-type tumors but provides no additional benefit
(Figure 6A). This suggests that in parental B16, STAT1 plays a pro-response role.
Interestingly, despite having no better response than parental B16 tumors, STAT1/PDL1
double KOs have a growth delay without treatment (Figure 6A). However, resistant 499
STAT/PDL1 2x KOs do not exhibit this same growth delay (Figure 6B), further
emphasizing the divergent roles for STAT1 in parental and relapse tumors. The growth
delay in the B16 STAT1/PDL1 2x KOs is T cell dependent as using a CD8 depleting
antibody in wild-type mice, or putting tumors into either Rag KO or Nude mice which do
not have T cells eliminates the growth delay (Figure 6C and 6D). One possible explanation
for the divergent phenotypes between parental and relapse tumors is differences in
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neoantigen burden, likely caused by immunoediting. This is supported by the fact that
499s have lost several predicted high-affinity neoantigens when compared to parental
B16s (Figure 6E). The 499 PDL1 KO late relapse cell line JB2 further lost several neoantigens compared to the original 499 PDL1 KO cell line further supporting this idea
(Figure 6E). Since STAT1 signaling is necessary for antigen presentation171, knockout out
STAT1 in the neo-antigen high parental B16s has a deleterious effect on the T cells’ ability
to recognize and eliminate the tumor.

Discussion
Understanding how tumors become resistant to ICB or combination therapies is
critical to identifying biomarkers of resistance as well as developing novel treatments to
combat resistance. Increased expression of PD-L1 by the tumor cells or other cell types
such as tumor infiltrating lymphocytes can mediate resistance to therapies that do not
block PD1/PDL1. This PD-L1 mediated resistance can be innate to the tumor as a result
of oncogene driven tumorigenesis, or adaptively upregulated by cytokines such as
interferon during an immune response145,168. Previously, we have reported that adding
anti-PDL1 to anti-CTLA4+RT leads to dramatic improvements in overall survival109. Here
we show that in our primary mouse models of metastatic melanoma and breast cancer
that tumor PD-L1 plays the dominant role in mediating resistance to anti-CTLA4+RT.
Adding anti-PDL1 does not appreciably improve response, suggesting that the observed
benefits of adding anti-PDL1 primarily come through blocking tumor PD-L1 in this model.
In our late relapse models, however, ablating PD-L1 through CRISPR/Cas9 improves
response but not nearly as dramatically as in the parental cell lines implicating additional
acquired mechanisms such as differences in PD-L1 in the tumor microenvironment or
additional

tumor-intrinsic

mechanisms.

Relapse

tumors

had

high

levels

of

immunosuppressive macrophages which are PD-L1 high and contribute to resistance.
The role of macrophages in resistance has also been observed in clinical samples
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although the polarization of the macrophages was not evaluated. Given the conflicting
clinical reports about the role of macrophages in tumor progression, further study is
necessary to evaluate the potential value of utilizing a macrophage depleting antibody as
an adjuvant therapy. In addition to PD-L1 on either the tumor or TILs there are likely PDL1 independent resistance mechanisms as evidenced by our clinical trial data of patients
who received anti-CTLA4+RT then anti-PD1 and still had progression regardless of PDL1 status.
One potential mechanism for resistance in these patients and in our relapsed
mouse tumors is neo-antigen loss through immunoediting95. Both 499 and JB2 lost two
high affinity and several lower affinity predicted Class I neo-antigens compared to their
respective parental cell lines. This observation helps explain the differential response in
499s compared to B16 when PD-L1 is knocked out, as well as why JB2 are resistant to
anti-CTLA4+RT even though they do not express PD-L1.

However, further work is

required to directly implicate these lost neo-antigens in promoting resistance, and closer
tracking of human patients during clinical trials is necessary to monitor the neo-antigen
load and how it relates to resistance in patients. Additionally, it remains unclear whether
Class I or class II neo-antigens are more important in mediating response172, and further
work is necessary to identify and study any class II neo-antigens that may also be involved
in mediating response in the parental cell lines which are lost in our relapse cell lines.
While neo-antigen loss is observed in both our patient and mouse models and correlates
with relapse and resistance it is experimentally challenging to intervene to correct this.
Combatting antigen loss would require activating the immune system against weaker neoantigens and self-antigens possibly through relaxing tolerance.
A promising avenue to improve response in relapse tumors is through inhibiting
STAT1. Knocking out STAT1 in our relapse 499 melanoma and 237 breast cancer models
significantly re-sensitized tumors to anti-CTLA4+RT. This improved response is likely
31

through a combination of reduced expression of T cell inhibitory ligands such as PD-L1 as
well as other unidentified mechanisms. STAT1 is a central regulator of both type I and
type II IFNs but also has other IFN independent roles173. Understanding whether STAT1
mediated resistance is through type I or type II IFN signaling, IFN independent
mechanisms, or some combination of these, as well as what resistance mechanisms these
pathways regulate will be critical for identifying approaches to re-sensitize resistant tumors
to ICB. Additionally, STAT1 KO had divergent effects in parental versus relapse tumors
with parental STAT1 KOs responding worse than wild-type to anti-CTLA4+RT while
relapsed KO tumors responded better. Understanding why this divergent phenotype
occurs, how relapsed parental tumors become dependent on STAT1 to maintain
resistance, and biomarkers of this process are all necessary to identify which patients
would benefit from therapies to block STAT1 signaling to improve response to ICB or the
combination of ICB and other therapies such as radiation.
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Figure 1: Tumor PD-L1 mediates resistance to the combination of anti-CTLA4 and
radiotherapy
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Figure 1: A and B) PDL1 expression on parental B16 melanoma (A) or relapse 499 (B)
with or without CRISPR knockout of PDL1. C) Survival after RT+anti-CTLA4 for mice with
B16 tumors or tumors with PDL1 knocked out. D) Survival after RT+anti-CTLA4 for mice
with 499 tumors or tumors with PDL1 knocked out. E and F) PDL1 expression on parental
TSA breast cancer (E) or relapse 237 (F) with without CRISPR knockout of PDL1. G)
Survival after RT+anti-CTLA4 for mice with TSA tumors or tumors with PDL1 knocked out.
H) Survival after RT+anti-CTLA4 for mice with 237 tumors or tumors with PDL1 knocked
out.
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Figure 2: Immune cells expressing PD-L1 mediate resistance to anti-CTLA4 and
radiotherapy in relapse but not parental tumor lines

Figure 2: A) Representative contour plot of in vivo PDL1 expression on melanoma cells
(red) and CD45+ immune cells (blue) from B16 or Res 499 tumors.

B) Median

fluorescence intensity of PDL1 on immune cells from B16 or 499 tumors. C) Survival after
either RT+anti-CTLA4 or RT+anti-CTLA4+anti-PDL1 in mice with B16 PDL1 knockout
tumors. D) Survival after either RT+anti-CTLA4 or RT+anti-CTLA4+anti-PDL1 in mice
with Res 499 PDL1 knockout tumors.
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Figure 3: Macrophages expressing PD-L1 portend relapse after treatment in both
murine models and patient samples

Figure 3: A) Histogram plot of relative PDL1 expression on the indicated immune cell
populations in Res 499 tumors. B) Percent of F4/80+ macrophages polarized as M1 or
M2 in a Res 499 tumor. C) MFI of PDL1 on the macrophages from B. D) Percentage of
CD45+ immune cells that are F4/80+ in Res 499 tumors 10 days after starting anti-CSF1R.
E) Survival of mice treated with RT+anti-CTLA4 with or without anti-CSF1R. F) Overall
survival of metastatic melanoma patients treated on a clinical trial of RT+ anti-CTLA4 was
modeled by random survival forest using the percentage of PDL1+ melanoma cells or
macrophages or the PDL1 IHC staining intensity score (0-3) on melanoma cells,
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macrophages, or both. The prediction error rate for the model is 38.7+/- 0.01% with n=13.
Shown are the variable importance scores with Monte Carlo standard deviations, as a
measure of how strongly the variable contributes to prediction accuracy. G) Predicted
survival of metastatic melanoma patients treated with RT+anti-CTLA4 modeled by random
forest using the combined IHC PDL1 intensity score on melanoma cells and macrophages.
Estimates are based on out-of-bag samples.
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Figure 4: PD-L1 independent resistance to immune checkpoint blockade occurs in
both mice and patients

Figure 4: A) Schematic of the development of the JB2 cell line, which is from a Res 499
PDL1KO tumor, relapsed 2 months after therapy. B) In vitro flow cytometry for PDL1
expression on parental 499 or JB2 confirming JB2 were still PDL1KO. C) Tumor growth is
mice treated with or without RT+anti-CTLA4 (n=5). D) Overall survival after starting antiPD1 for patients initially treated with RT+anti-CTLA4 on a clinical trial. Progression, time
of progression, and death after anti-PD1 are indicated.
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Figure 5: Differential effects of STAT1 knockout in parental and relapse tumors
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Figure 5: A) Relative expression of IFN and IFN receptor genes from whole tumor lysates.
Mean (gray line) and first and third quartiles (dashed lines) of all genes on the microarrays
are indicated. Error bars are SDs. B) Relative expression of IFN and IFN receptor genes
from whole tumor lysates. Mean (gray line) and first and third quartiles (dashed lines) of
all genes on the microarrays are indicated. Error bars are SDs. IFNg levels in the blood
of mice bearing B16 tumors after RT+anti-CTLA4 (n=7). *p<0.05. C) Expression of PDL1
(an ISG responsive to type I and type II IFN signaling) on B16 and B16 cells with STAT1
knockout (left) or Res 499 and 499 STAT1 knockout (right). D) Expression of PDL1 (an
ISG responsive to type I and type II IFN signaling) on TSA and TSA cells with STAT1
knockout (left) or Res 237 and 237 STAT1 knockout (right). E) Survival after RT+antiCTLA4 for mice with B16 or B16 STAT1KO tumors (left) or TSA and TSA STAT1KO tumors
(right). F) Survival after RT+anti-CTLA4 for mice with Res 499 or 499 STAT1KO tumors
(left) or Res 237 and 237 STAT1KO tumors (right). G) Survival after treatment with antiPD1 monotherapy in mice with B16 or B16 STAT1KO tumors. H) Survival after treatment
with anti-PD1 monotherapy in mice with Res 499 or 499 STAT1KO tumors.
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Figure 6: Neoantigen loss correlates with resistance to treatment

Figure 6: A) Survival after treatment with RT+anti-CTLA4 in mice with B16 or B16
STAT1/PDL1KO tumors. B) Survival of untreated mice injected with Res 499 or 499
STAT1/PDL1Ko tumors. C) Survival of mice after injection with B16 STAT1/PDL1KO tumors
with or without anti-CD8a antibody treatment. D) Survival of wild-type (C57bl/6), athymic
(nude), or Rag2 (Rag KO) mice after injection with B16 (left) or B16 STAT1/PDL1KO (right)
tumors. E) Predicted MHC-I affinity of non-synonymous somatic mutations that have
undergone loss or near-loss of heterozygosity (LOH) in Res 499 compared to parental
B16. For each mutation, all 8, 9, and 10-mer peptides containing the amino acid mutation
were determined and the H-2Kb and H-2Db affinity calculated using IEDB and the artificial
neural network method. Shown is the reciprocal of the affinity for all peptides. Those
exceeding 500 nM (blue dashed line) and 20 nM (red dashed line) are labeled. Peptides
from genes showing no evidence of expression by RNA-seq were omitted.
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Chapter 3

Introduction
Immune checkpoint blockade (ICB) is rapidly becoming an effective therapeutic
option for several cancer types168. Despite this success, resistance and relapse are
common. One important mechanism of resistance is the upregulation of PDL1168,174, a
ligand for the T cell inhibitory receptor PD1. T cell inhibitory receptors (TCIRs), or immune
checkpoint receptors, such as PD1, promote tolerance to self-antigens and limit immunemediated pathology that can result from persistent antigen and chronic inflammation58.
PD1 serves this negative regulatory function by promoting T cell exhaustion. Exhausted T
cells (TEX) have reduced proliferative and functional capacity that includes diminished
cytokine and cytolytic activity. This dysfunctional state can be partially reversed, or
reinvigorated, to improve effector function. Hence, the clinical activity of PD1/PDL1
blockade in cancer may be related to the reinvigoration of TEX that develops as a result of
a pre-existing immune response or to preventing the development of TEX after therapy is
initiated.
An additional hallmark of TEX is the expression of multiple inhibitory receptors, such
as CTLA4, TIM3, LAG3, TIGIT, and others58,175. The co-expression of multiple TCIRs on
TEX suggests that these additional inhibitory pathways may drive PD1/PDL1-independent
resistance mechanisms that can be targeted to improve responses. Across several cancer
types, up to 50% of patients with PDL1+ tumors are either resistant or relapse after
PD1/PDL1 blockade71,176,177, consistent with the need to antagonize parallel PDL1independent resistance mechanisms. However, how to rationally combine ICB agents with
each other or other therapies is not obvious. In particular, the T EX population appears
heterogeneous in TCIR expression, exhaustion-related markers, and reinvigoration
potential178-181. For example, in chronic viral infections, TEX expressing high levels of
multiple TCIRs are considered less susceptible to reinvigoration by PD1/PDL1 blockade.
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Thus, approaches to effectively prevent the development of or reinvigorate a broader and
more recalcitrant subset of TEX may have therapeutic importance for immunotherapy.
The balance between immune-mediated tumor elimination and escape is
influenced by many factors. Interferons (IFNs) are typically considered important in the
generation of an anti-tumor immune response. Type I IFN (IFN-I) promotes dendritic cell
function and CD8 T cell cross-priming, whereas interferon-gamma (IFNG), a type II IFN,
influences both host and tumor cells to favor rejection of highly immunogenic tumors 182.
Both IFNs appear to be particularly critical for early T cell priming and activation events
with less effect on tumor response when either is antagonized at later times183. In contrast,
under conditions of prolonged IFN signaling and persistent antigen exposure,
accumulating evidence indicates that IFNs can have immunosuppressive roles184. For
example, in cancer the upregulation of PDL1 by IFNG is an “adaptive resistance”
mechanism. Here, tumor cells respond to IFNG as part of a negative feedback event to
inhibit the immune response145. Countering adaptive resistance appears to be a major
therapeutic effect of PD1/PDL1 blockade. In total, these observations suggest that
opposing immunomodulatory functions of IFNs may influence the balance between
immune-mediated elimination and immune escape.
Recently, we examined the molecular and immune determinants of response to
the combination of anti-CTLA4 and radiation (RT) for metastatic melanoma109. Although
the combination regimen can result in durable responses with RT contributing to T cell
repertoire diversification and ICB driving oligo-clonal T cell expansion, a majority of mice
and patients treated with RT + anti-CTLA4 were either resistant or relapsed. The
upregulation of PDL1 in the tumor was determined to be an important resistance
mechanism to RT + anti-CTLA4 and was associated with persistent T cell exhaustion or
poor reinvigoration as measured in the post-treatment blood of mice and patients.
However, although the addition of anti-PD1/PDL1 to RT + anti-CTLA4 improved
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responses in mice, resistance and/or relapse still occurred, indicating the existence of
additional immunosuppressive pathways.

Results
Prolonged Tumor IFN Signaling Drives PDL1-independent Resistance to ICB
IFNG drives PDL1 expression, which may be regulated by either type I or II IFNs.
Therefore, we sought to investigate whether IFNs could orchestrate resistance beyond the
upregulation of PDL1. Both Res 499 and JB2 were derived from tumors that initially
responded to RT + ICB but subsequently relapsed several weeks after initiation of therapy.
Type I and II IFN transcripts are present in both B16 and Res 499 whole tumors (Figure
5B) and can increase significantly after therapy, in particular IFNG (Figure 5A). To
potentially mimic IFN conditions in the tumor microenvironment post-therapy, we treated
parental B16 cells with various doses of either IFNG or type I IFN (IFN-I) for two weeks in
culture, followed by removal of IFN and continuous culture for another week. Treating B16
cells with prolonged IFNG (B16γ) was sufficient to confer resistance to RT + anti-CTLA4
to levels approaching Res 499 (Figure 7A-B). In contrast, prolonged IFN-I signaling did
not confer resistance (Figure 8A) and signaling through type III IFNs was not detected
(Figure 8B). These results demonstrate that exposure to persistent IFNG is sufficient to
render sensitive melanoma resistant to RT + anti-CTLA4.
Prolonged tumor growth accompanied by an ineffective T cell response would be
expected to result in persistent IFN exposure in vivo. Therefore, to examine whether
acquisition of resistance in vivo can occur after prolonged tumor growth and IFN exposure,
we used three different treatment schedules that first allowed tumors to grow to
substantially larger sizes prior to therapy (Figure 7C). For the treatment, anti-PDL1 instead
of RT was combined with anti-CTLA4 to eliminate rapid cytoreduction from RT and to
examine for PDL1-independent resistance. As expected, mice with B16 tumors responded
to a standard dosing schedule at day 5 but failed to respond when therapy was delayed
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until day 10 (Figure 7D). In contrast, mice bearing B16 tumors with knockout of the IFNG
receptor (IFNGRKO) (Figure 8C) maintained their ability to respond despite the delay.
Importantly, IFNGRKO had no effect on B16 tumors when therapy was not delayed (Figure
7D, D5 schedule), supporting the notion that signaling through the tumor IFNG receptor
was not influencing primary resistance but rather driving PDL1-independent adaptive
resistance.
Even though prolonged IFN-I signaling in vitro did not appear sufficient to confer
resistance, we investigated whether the IFN-I receptor (IFNAR) might influence B16 tumor
response when ablated with IFNGR. In the absence of therapy, double IFNGR and IFNAR
knockout (IFNA/GRKO) tumors (Figure 8D) displayed similar tumor growth as control
tumors (Figure 8E) and similar to IFNGRKO tumors (Figure 8F). However, when treatment
was delayed until day 13 (but not earlier), IFNA/GRKO appeared more effective than
IFNGRKO at sustaining responsiveness to therapy (Figure 7E). This effect of IFNAR was
observed only after prolonged tumor growth and therapy delay prompting us to examine
the role of each IFN receptor in maintaining resistance.
Type I and II IFN Signaling in Tumor Cells Maintains PDL1-independent Resistance
To distinguish a role for type I and/or II tumor IFN signaling in maintaining as
opposed to initiating resistance, we utilized Res 499 tumors with IFNGRKO or IFNAR
knockout (IFNARKO) (Figure 8G-H). This revealed that disrupting either IFN receptor did
not alter Res 499 tumor growth in the absence of treatment (Figure 7F) but restored
response of these resistant tumors to RT + anti-CTLA4 to levels similar to parental B16
tumors (Figure 7G and 7B). Examination of in vivo transcriptomic changes demonstrated
that each receptor partially diminished expression of top upregulated genes representing
transcriptomic features acquired by Res 499 tumors as a consequence of relapsing after
RT + anti-CTLA4 (Figure 7H). IFNA/GRKO (Figure 8I) led to the largest decrease in genes
associated with resistance and had the largest effect on multiple biological processes
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related to IFN signaling as well as other pathways (Figure 10A). Given the more
comprehensive effect of IFNA/GRKO, we knocked out both IFN receptors in JB2 cells to
directly establish their role in maintaining PDL1-independent resistance (Figure 8J).
Indeed, despite JB2 cells lacking PDL1 and having acquired resistance through PDL1independent means, IFNA/GRKO restored response of JB2 tumors to RT + anti-CTLA4
(Figure 7I). Thus, these results indicate that type I and II IFN signaling contributes to
maintaining a PDL1-independent resistance state.
Prolonged IFN Drives STAT1-Related Epigenomic and Transcriptomic Features of
Resistant Tumors
The effect of prolonged IFNG signaling in vitro and in vivo on PDL1-independent
resistance suggests possible epigenetic influence. Indeed, persistent IFNG stimulation
resulted in elevated levels of constitutive STAT1 as observed in B16γ cells even after
continuous culture in the absence of exogenous IFNG (Figure 9A). To investigate if
elevated STAT1 might be associated with how the epigenome responds to in vivo signals
in the tumor microenvironment, we performed ATAC-seq on sorted melanoma cells to
assess differences in open chromatin regions (OCRs). This revealed that prior chronic
IFNG exposure alters the in vivo epigenome of B16 to partially resemble that of Res 499
(Figure 9B). Analysis of differential OCRs in B16γ and Res 499 relative to B16
demonstrated that a significant fraction (45.9%) of differential OCRs acquired by B16γ
overlapped with those acquired by Res 499 (Figure 9C). A de novo motif search showed
that many motifs within the differential OCRs found in B16γ and Res 499 significantly
matched to STAT1 sites (Figure 10B) and many were shared between B16γ and Res 499
(Figure 9C, p=5.3 x 10–47 for overlap by hypergeometric test). ATAC-seq revealed DNA
footprinting centered at discovered STAT1 motifs, and these footprints increased in Res
499 and B16γ relative to B16, consistent with increased STAT1 occupancy within these
OCRs (Figure 9D). This increase in inferred STAT1 occupancy and STAT1 levels in B16γ
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was correlated with the in vivo acquisition of transcriptomic features associated with
relapse from RT + anti-CTLA4 (Figure 10C, left). Indeed, these transcriptomic features
showed a high degree of STAT1-dependency as demonstrated by STAT1KO in Res 499
tumors (Figure 10C, right). STAT1KO in Res 499 also inhibited resistance to RT + antiCTLA4 (Figure 9E-F), and STAT1KO together with PDL1KO (Figure 10D) led to better tumor
response compared to either knockout alone, consistent with STAT1 regulating PDL1independent resistance. Thus, prolonged IFNG alters the melanoma epigenome in vivo to
partially resemble that of resistant tumors. STAT1 occupancy may underlie a significant
proportion of these changes to influence transcriptomic features of resistant tumors and
to regulate PDL1-independent resistance pathways.
A Multigenic Resistance Program of TCIR Ligands and ISGs
Genome-wide effects of persistent IFN signaling and acquisition of PDL1independent resistance appeared to converge onto enhanced STAT1 expression and/or
activity. Thus, we reasoned that genes associated with STAT1 could provide insight into
effectors involved in PDL1-independent resistance. Due to the large number of genes
differentially expressed in Res 499 compared to B16, we integrated transcriptomic data
from mice and patients to examine only genes that included: 1) annotated type I and II
IFNs, 2) ISGs that we previously described to be robustly expressed across human
cancers140, and 3) common T cell inhibitory receptors (TCIRs), their ligands, and
immunosuppressive effectors such as IDO1. Analysis of unsorted Res 499 and B16
tumors revealed that in resistant tumors Stat1 preferentially correlated with genes
encoding multiple TCIR ligands that included TNFRSF14 (HVEM), LGALS9 (Galectin-9),
and MHC class II (MHCII) – ligands for CD160 and BTLA, HVARC2 (TIM3), and LAG3,
respectively (Figure 9G). A similar pattern was observed with the ISGs Ifit1 and Mx1.
Using expression data from TCGA, we sought to corroborate the significance of
the TCIR ligands and ISGs that preferentially associate with STAT1 in resistant mouse
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tumors. Because many of the examined genes may simply correlate with the presence of
a T cell infiltrate, we also added CD8A, GZMA, and PRF1, which can act as a surrogate
for T cell infiltration and cytolytic activity185. Despite a high degree of correlation among
most of the examined genes (Figure 9H), network analysis reveals that STAT1 is the only
gene that connects the IFNG/CD8 T cell infiltrate genes, ISGs, and a cluster of TCIR and
TCIR ligands through PDL1 (Figure 9I). To mimic the effect of elevated PDL1 found in Res
499 compared to B16, we examined how correlations between STAT1 and other genes in
the network change when PDL1 gene expression is high versus when it is low (Figure 9J).
Indeed, when PDL1 is high, STAT1 more strongly and significantly correlates with
TNFRSF14, LGALS9, MHCII, CD86, and the ISGs MX1 and IFIT1 compared to when
CD8A levels are high, suggesting that these associations are not simply due to higher T
cell infiltration. Thus, in both Res 499 tumors and human melanoma tumors with high
PDL1 expression, an overlapping set of TCIR ligands and ISGs preferentially associate
with STAT1. We denote this set of multiple TCIR ligands (PDL1, TNFRSF14, LGALS9,
MHCII, CD86) and cancer-associated ISGs (IFIT1 and MX1) as IDILS, or Interferon-Driven
Inhibitory Ligands and ISGs. Transcriptomic analysis of sorted tumor cells revealed that
IDILS increases in B16γ compared to B16 and decrease as a consequence of STAT1 KO
(Figure 9K). Treatment of Res 499 cells in vitro with IFNG or IFN-Is confirmed that IFNs
directly regulate the TCIR ligands that comprise IDILS (Figure 11A). Thus, IDILS is IFN
and STAT1-dependent and increases as a result of prolonged IFNG signaling.
Inhibiting Tumor IFN Signaling Antagonizes Multiple TCIR Ligands and Resistance
Examining in vivo expression of IDILS TCIR ligands confirmed elevated expression
in Res 499 compared to B16 (Figure 11B, top two rows). B16γ showed increased
expression for most, but not all, of these ligands, and this expression was generally
intermediate between B16 and Res 499. Interestingly, although most TCIR ligands are
influenced by both type I and II IFNs, some ligands like LGALS9 are preferentially affected
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by IFN-I, while others such as MHCII are predominantly influenced by IFNG (Figure 11A).
Indeed, distinct effects by type I versus type II IFNs on TCIR ligands and other IDILS
genes are observed in vivo when each receptor is disrupted, and the most severe effects
on IDILS occurs with IFNA/GRKO (Figure 11C). The effect of IFNA/GRKO and the STAT1dependency of TCIR ligands was also confirmed by flow cytometry of in vivo tumors
(Figure 11B, bottom two rows). Thus, inhibiting both IFN receptors in tumor cells effectively
collapses IDILS and its multiple TCIR ligands.
To assess whether IDILS TCIR ligands can contribute to PDL1-independent
immune suppression, we used a combination of genetic and blocking antibody
approaches. Given the near-absent baseline expression of TNFRSF14 and reports that it
can interact with multiple TCIRs that include CD160 and BTLA186, we utilized CRISPR to
ablate TNFRSF14 in Res 499 PDL1KO tumors (Figure 12A). The additional blockade of
the TNFRSF14 pathway improved response to RT + dual blockade of PDL1 and CTLA4
(Figure 11D). To interrogate LGALS9 and MHCII, a blocking antibody to TIM3 and LAG3
were used, respectively. For these experiments, RT was omitted due to unexpected high
toxicity when RT was combined with triple ICB (data not shown). Nonetheless, blocking
either the LGALS9/TIM3 or MHCII/LAG3 pathways improved response to dual blockade
of CTLA4 and PDL1, while quadruple blockade had the best effect (Figure 11E-F).
Blocking TIM3 and LAG3 also improved ICB efficacy in the Res 237 resistant breast
cancer model (Figure 11G). Similar to Res 499, Res 237 tumor cells originated from a
breast tumor that initially responded to RT + anti-CTLA4 but relapsed weeks later. Thus,
IDILS TCIR ligands can contribute to PDL1-independent resistance.
Although initial response to ICB is improved by blocking multiple IDILS TCIR
ligands, most mice relapse (Figure 11F-G); however, we reasoned that IFNA/GRKO would
be more effective, due to disruption not only of multiple TCIR ligands but other IDILS and
IFN-associated pathways as well (Figure 7H, Figure 10A). Indeed, IFNA/GRKO markedly
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improved response and survival to anti-CTLA4 + anti-PDL1 compared to addition of TIM3
and/or LAG3 blockade (Figure 11H). Thus, interfering with multiple TCIR ligands and
potentially other suppressive mechanisms associated with IDILS effectively improves ICB
response and survival.
Inhibiting IFN-Driven Resistance Expands Distinct Populations of Exhausted T Cells
after ICB
Exhausted T cells are a heterogeneous population that differs in their capacity for
reinvigoration after ICB. Part of this heterogeneity is due to increased severity of
exhaustion with increasing co-expression of multiple TCIRs. We reasoned that interfering
with multiple TCIR ligands as part of blocking IDILS could enhance expansion of the T cell
repertoire particularly by affecting severely exhausted T cells co-expressing multiple
TCIRs. To investigate this, we first developed an approach to identify populations of T
cells expressing distinct TCIR co-expression patterns (Figure 12B). Nine robust T cell
clusters were identified (Figure 13A-B, Figure 14A). T cells in four clusters express either
high or intermediate levels of PD1 (Cl.1, Cl.5.2, Cl.5.3, Cl.5.5). Among these, clusters Cl.1
and Cl.5.5 exhibit co-expression of multiple TCIRs but lack high expression of any
individual TCIR (PD1intTCIRlow cluster). In contrast, Cl.5.2 and Cl.5.3 are PD1highTCIRhigh
clusters showing highly elevated expression of multiple TCIRs (Figure 13B), a cardinal
feature of severely exhausted T cells175.
Although all T cell clusters could be identified in the tumor, tumor-reactive CD8
TILs, as measured by a tetramer to the known melanoma antigen TRP2187, predominantly
belonged to the PD1highTCIRhigh Cl.5.2 and Cl.5.3 clusters (Figure 14B). The proportion of
T cells in these PD1highTCIRhigh clusters either increased or remained the same after
treating mice with Res 499 tumors with anti-CTLA4 + anti-PDL1. Furthermore, the
proportion of Ki67+GzmB+ TILs in either the total CD8 TIL population (Figure 13C) or in
TILs from individual clusters failed to increase (Figure 13D-E). In contrast, IFNA/GRKO or
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STAT1KO altered the frequency of TRP2+ CD8 TILs in response to dual ICB, resulting in
an increase in the proportion of PD1highTCIRhigh Cl.5.2 T cells (Figure 14B-C). This was
accompanied by an ICB-mediated increase in the proportion of Ki67+GzmB+ TILs (Figure
13C) that preferentially affected the Cl.5.2 cluster (Figure 13D-F). Thus, blocking tumor
IFN signaling along with ICB leads to a preferential accumulation of PD1highTCIRhigh Cl.5.2
TILs with markers of improved function.
To better assess population expansion dynamics, we performed serial analysis of
peripheral blood on mice before and after anti-CTLA4 + anti-PDL1. After dual ICB (given
on day 13), mice with Res 499 IFNA/GRKO tumors demonstrated a large expansion in
PD1+ peripheral T cells compared to mice with wild type Res 499 tumors (Figure 13G).
Furthermore, IFNA/GRKO led to a larger fraction of PD1+ T cells that were Ki67/GzmB
positive despite concomitantly expressing Eomes, a transcription factor typically
expressed by severely exhausted T cells with limited proliferative potential. This increase
was apparently driven by a larger proportion of PD1+ T cells belonging to the
PD1highTCIRhigh Cl.5.2 and Cl.5.3 clusters (Figure 13H) and by the preferential increase in
the fraction of Eomes+ Ki67+GzmB+ T cells in both of these populations (Figure 13I). In
contrast, the PD1low/int and/or TCIRlow populations Cl.1, Cl.5.1, and Cl.5.5 failed to show a
similar increase. For the PD1highTCIRhigh Cl.5.2 population, the expansion of Eomes+
Ki67+GzmB+ T cells resulting from IFNA/GRKO was associated with an increase in both the
proportion of Eomes+ versus Eomes– T cells and in the fraction of Eomes+ T cells that
were Ki67+GzmB+ (Figure 13J-K). For the PD1highTCIRhigh Cl.5.3 group, the vast majority
of T cells already expressed Eomes irrespective of IFN receptor status. In total, these
observations suggest that crippling multiple TCIR ligands and IDILS results in
accumulation of distinct populations of PD1highTCIRhighEomes+ TEX that otherwise would
be recalcitrant to reactivation.
Targeting IFN-Driven Resistance Restores Response to ICB Monotherapy
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Tumor IFN signaling drives expression of IDILS genes, contributes to PDL1independent resistance to RT + anti-CTLA4, and can be ablated to preferentially expand
otherwise severely exhausted T cells and improve response to combination ICB. We
reasoned that if inhibiting IDILS is functionally equivalent to blocking multiple TCIR
pathways and other suppressive genes en bloc, such an effect might even restore
sensitivity to ICB monotherapy. Indeed, although triple or quadruple ICB was required to
significantly improve response of Res 499 tumors (Figure 11E-F), IFNGRKO and/or
IFNARKO allowed for response to anti-PD1 monotherapy and to anti-CTLA4 monotherapy
(Figure 15A) with the largest effect typically observed with IFNA/GRKO. In fact, when both
type I and II IFN receptors were eliminated from Res 499 tumors, complete responses and
long-term survival were observed after anti-CTLA4 monotherapy (Figure 15B).
Remarkably, with Res 237 breast cancer tumors, which also show elevated levels of
genes involved in IFN-driven resistance (Figure 16A), IFNA/GRKO led to 100% complete
response and survival after anti-CTLA4 alone (Figure 15C). Improved response to ICB
monotherapy after inhibiting tumor IFN signaling was CD8 T cell dependent (Figure 16BC). Accordingly, MHC class I surface expression was maintained in vivo despite blocking
tumor IFN signaling, albeit at expectedly lower levels (Figure 16D-E). This constitutive
MHC-I is consistent with baseline expression of MHC-I and antigen processing machinery
observed across melanoma and breast cancer cell lines largely in the absence of IFNs
(Figure 16F).
Similar to genetic ablation, administration of a JAK1/JAK2 inhibitor (JAKi)
ruxolitinib decreases multiple TCIR ligands on tumor cells (Figure 15D, Figure 16G). At
the dose used, effects on immune cells appeared less pronounced, although downward
trends in expression were evident. A delayed administration of JAKi after start of ICB
(Figure 15E, D8 schedule) resulted in improved response of both Res 499 melanoma and
Res 237 breast cancer tumors (Figure 15F-G). Starting JAKi at the same time as anti52

CTLA4 did not result in improved response (Figure 15E-F, D5 schedule), consistent with
the requirement for early IFN signaling for immune cell function183. In total, these results
demonstrate that inhibiting IFN signaling genetically or pharmacologically can restore
response to ICB monotherapy even with tumors that are highly resistant to extensive ICB
combination therapy.
High Expression of ISGs Can Associate with Clinical Progression After Anti-PD1
The IDILS resistance program is comprised of two ISGs, IFIT1 and MX1. Since
these ISGs are co-expressed with the TCIR ligands and also regulated by tumor IFN
signaling, we examined whether their expression could be associated with lack of clinical
response to ICB. To test this, we used the average expression of IFIT1 and MX1 and
computationally modeled clinical response to anti-PD1 using a recently published cohort
of melanoma patients142. To guard against bias, out-of-bag (OOB) samples, or samples
not used in constructing the model, provided estimates of model error rate and variable
importance scores. Given the known association between neo-antigen burden and antiPD1 response188, we included the number of non-synonymous somatic mutations, or
single-nucleotide variants (nsSNVs), in the model. The OOB error rate for overall accuracy
and association with response or progression were all approximately 39%, which likely is
influenced by the small sample size (Figure 17A). Both nsSNVs and IFIT1/MX1
contributed to prediction accuracy, as measured by a variable importance score (Figure
17B). Examination of partial plots, which adjusts for the effects of other variables in the
model, reveals that likelihood of response increases with low IFIT1/MX1 expression and
high nsSNV load (Figure 17C). These relationships are further demonstrated in a scatter
plot whereby the majority of patients that responded (blue circles) distribute to the lower
right quadrant, representing high nsSNV load and low IFIT1/MX1 expression (Figure 17D).
Accordingly, these patients also generally have a higher OOB predicted likelihood of
response (larger circles).
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Because of high correlations between IFIT1/MX1 with the multiple genes originally
examined for IFN-driven resistance (Figure 17E and 9H), we used bootstrapping and
previously described variable selection methods189 to better assess performance of
IFIT1/MX1 and nsSNVs against these other TCIRs, TCIR ligands, and ISGs. This revealed
that nsSNVs and IFIT1/MX1 are the most frequently selected variables among bootstrap
samples, suggesting that they robustly associate with response (Figure 17E, right).
Interestingly, IFN-I is also frequently selected, has a high importance score relative to the
other genes, and negatively correlates with anti-PD1 response (Figure 17F). In total, these
results provide correlative clinical evidence that high expression of IDILS genes and IFN
signaling associate with progression to anti-PD1.

Discussion
Several clinical observations reflect the complex biology of IFN signaling in
immunotherapy184. A major source of IFNG in the tumor microenvironment is T cells 145.
Since T cell infiltration is essential to generate an anti-tumor response, IFNG-related gene
expression can correlate with response to immunotherapy190,191. However, IFNG also
regulates inducible expression of PDL1 on tumor and immune cells. Accordingly, with
immunotherapy regimens that do not block the PD1/PDL1 pathway, PDL1 and ISGs can
portend relapse109,192,193. In contrast, when regimens include anti-PD1/PDL1, the presence
of PDL1 and IFNG-related genes can favorably predict response due to the effectiveness
of these agents at inhibiting PD1 activation. However, for a majority of patients, antiPD1/PDL1 does not appear sufficient despite having PDL1/IFNG-expressing tumors177.
Our study reveals that this can result from PDL1-independent adaptive resistance
associated with distinct TCIR ligands, ISGs, and IFN-I gene expression. In total, these
clinical observations highlight how IFNs can track with favorable immune parameters, but
yet orchestrate PDL1-dependent and PDL1-independent immune suppression.
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Our data suggest that the development of PDL1-independent resistance is
influenced by the nature and duration of IFN signaling in the tumor microenvironment.
Adequate early production of type I IFNs promotes dendritic cell activation and T cell
cross-priming183. IFNG signaling on host and tumor cells can also be important early
during immune activation, particularly in tumors with limited baseline MHC-I expression194.
However, our data support the notion that sustained IFN signaling contributes not only to
PDL1 expression but also to PDL1-independent adaptive resistance. Mechanistically,
prolonged IFNG signaling changes how tumor cells epigenetically respond to in vivo
signals. STAT1 occupancy appears to associate with these epigenomic differences and
is responsible for elevated expression of cancer-related ISGs and multiple TCIR ligands
on resistant tumors. Interestingly, STAT1 has been shown to increase after persistent IFN
stimulation to maintain a subset of ISGs including IFIT1 and MX1195. Given the extensive
number of type I, II and III IFNs, multiple members from this large family may have similar
or distinct effects. Thus, the nature of IFN signaling may regulate the balance between
immune-mediated tumor elimination and escape, and when PDL1-independent adaptive
resistance dominates over PDL1 alone.
The ability of ICB to prevent or to reverse T cell dysfunction or exhaustion is
thought to be an important pharmacological mechanism of action for these agents58. This
is best defined in models of chronic infection where increasing antigen burden and
duration of viremia results in the accumulation of PD1high TEX with elevated expression of
multiple TCIRs and conversion from Eomes– to Eomes+. These PD1highEomes+ TEX with
co-expression of multiple TCIRs are severely exhausted and have limited proliferative
potential175. Thus, PD1 blockade preferentially reinvigorates PD1intEomes– TEX that are
Tbet+ to give rise to PD1highEomes+ TEX178,196. Recent studies also demonstrate that a
PD1+CXCR5+ CD8 T cell population that resides in lymphoid niches with low expression
of inhibitory receptor ligands like PDL1 are targets for reactivation by PD1 blockade179,181.
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Thus, given the heterogeneity of the TEX population, determining the TEX subset that is
more responsive to ICB and/or devising approaches to reinvigorate deeply exhausted
PD1highEomes+ TEX populations may be an effective strategy to improve response to
immunotherapies. Addressing this notion, we show that in mice with ICB-resistant tumors,
inhibiting tumor IFN signaling along with ICB increases the fraction of PD1highTCIRhigh
Cl.5.3 and/or Cl.5.2 TEX that is Ki67+GzmB+ in both the tumor and periphery, consistent
with reinvigoration of TEX and/or prevention of exhaustion. In contrast, T cells from TCIRlow
clusters are less impacted. Moreover, knockout of tumor IFN signaling results in Cl.5.2
and Cl.5.3 peripheral T cells that are almost exclusively Eomes+. In contrast, peripheral
PD1highTCIRhigh Cl.5.2 and Cl.5.3 TEX from mice with intact tumor IFN signaling show more
mixed Eomes status after ICB. Whether tumor IFNA/GRKO primarily promotes the
conversion of reinvigorated Eomes– TEX to Eomes+ TEX in populations such as Cl.5.2,
facilitates direct reinvigoration of Eomes+ TEX, or prevents the development of the
exhausted state will require further investigation. Regardless, in mice with ICB-resistant
tumors, blocking tumor IFN signaling can expand the T cell repertoire by preferentially
increasing the proportion of PD1highTCIRhighEomes+ Ki67+GzmB+ T cells that otherwise
would be severely exhausted (Figure 17G).
Recently, two melanoma patients who initially responded to anti-PD1 but suffered
late relapse were discovered to have mutations in JAK1 or JAK2101. In another study,
melanoma patients who failed to respond to anti-CTLA4 were found to have copy number
alterations in IFN pathway genes102. Together with the findings described here, these data
suggest an emerging framework for resistance to ICB that consists of primary resistance,
acquired resistance, and PDL1-dependent and PDL1-independent adaptive resistance.
Primary resistance occurs due to selective pressures often related to tumor growth or
survival that coincidently render cancers non-responsive to therapy. In contrast, acquired
resistance occurs as a result of direct selective pressure imposed by treatment. Both are
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often due to mutational or genetic events. The copy number loss in IFN pathway genes
and mutations in JAK1/JAK2 represent loss-of-function (LOF) examples of primary and/or
acquired resistance mechanisms to ICB. In both cases, it has been suggested that such
genetic events may be selected to circumvent IFN-mediated cytostasis and
cytotoxicity101,102, resulting in these tumors failing or relapsing after ICB due to reliance on
IFN-regulated antigen processing or other positive immune effects. However, in contrast
to LOF resistance mechanisms, adaptive resistance has been proposed to be a negative
feedback response that antagonizes anti-tumor T cells though functioning IFNG signaling
pathways, resulting in the upregulation of PDL1. These tumors, like the tumors used in
this study, may be poorly responsive to the growth inhibitory effects of IFNs. Rather,
prolonged IFN signaling enables STAT1-related changes to the in vivo epigenome and
transcriptome that promote PDL1-independent adaptive resistance through IDILS.
Whether IFN signaling is lost or retained may depend on the existence of other
immune suppressive pathways or anti-cytostatic responses. Alternatively, rather than LOF
and adaptive resistance mechanisms competing, an interplay between the two may exist.
Our results demonstrate that type I and II IFNs can separately contribute to maintaining
IFN-driven resistance. Therefore, an acquired JAK2 mutation may promote relapse yet
still allow type I IFN to maintain PDL1-independent adaptive resistance. LOF mutations
that affect both IFNAR and IFNGR signal transduction, such as a JAK1 mutation, may
also influence ICB response and resistance in complex ways. For example, JAK1 LOF
may promote on-going response to PD1 blockade and a long progression-free survival,
as was reported in the patient harboring a JAK1 mutation101. However, the late clinical
relapse in this same patient may reflect a critical issue on the durability of tumor responses
when tumor eradication relies upon the reinvigoration of TEX. We show that IFNA/GRKO
improves response of resistant tumors but preferentially expands T cells belonging to
PD1highTCIRhighEomes+ T cell subsets. In chronic viral infection models, PD1 blockade of
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PD1highEomes+ TEX fails to convert these cells into durable and self-renewing memory T
cells197. Thus, a LOF JAK1 mutation may contribute to both initial response but also to late
relapse should residual disease persist beyond the functional/proliferative capacity of
reinvigorated PD1highTCIRhighEomes+ T cells that undergo preferential expansion when
tumor IFN signaling is ablated. These opposing immunomodulatory effects of IFN
signaling highlight a complex yet central role for this pathway in influencing ICB
response184, which likely reflects why both LOF and IFN-driven resistance pathways exist.
Combining different ICB agents with each other or other therapies is often empiric
and can increase severe and life-threatening toxicity with unclear benefit in unselected
patients198. Limiting the availability of multiple TCIR ligands by disrupting tumor IFN
signaling may functionally block multiple TCIRs and serve as a general strategy to broadly
target T cell inhibitory pathways. Besides the IDILS genes studied here, unidentified ISGs,
and/or immune populations other than T cells may also promote IFN-driven resistance. A
multigenic IFN-driven resistance program that goes beyond what we initially characterize
in this study likely contributes to why interfering with tumor IFN signaling combined with
ICB monotherapy is more effective than even quadruple antibody-based ICB. Thus,
crippling a broad multigenic resistance program may help to address some of the
challenges with formulating combination therapies. Practically, this may be accomplished
with JAK inhibitors. The dose and schedule are likely critical and will need optimization,
as indiscriminately blocking IFN signaling on host cells can interfere with the generation
of anti-tumor183 and anti-viral responses149,151,199. Nonetheless, proper timing using a JAK
inhibitor and biomarkers such as MX1 and IFIT1 to identify tumors under the influence of
IFN-driven immune suppression may represent a feasible strategy for inhibiting PDL1independent resistance.
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Figure 7: Prolonged tumor IFNG signaling is sufficient to instigate resistance to
RT + anti-CTLA4, while type I and II IFN signaling maintains PDL1-independent
resistance
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Figure 7: A) Tumor volumes (day 17, split y-axis) and B) survival of mice with indicated
tumors treated with RT + anti-CTLA4 (n=5-10). C) Standard (D5) and delayed treatment
schedules for anti-CTLA4 + anti-PDL1. Sizes of B16 tumors prior to treatment for each
schedule are shown (left). D) Tumor volumes for B16 tumors with or without IFNGRKO
treated with anti-CTLA4 + anti-PDL1 according to indicated schedule. E) Tumor volumes
relative to the average of untreated controls for B16 tumors with IFNGRKO or IFNA/GRKO.
F) Survival of mice with Res 499 tumors with or without indicated KO, or G) after treatment
with RT + anti-CTLA4 (n=5-10). H) Gene set analysis examining transcriptomic features
associated with resistance to RT + anti-CTLA4, derived from comparing resistant B16
tumors (e.g., Res 499) with parental tumors. Individual gene scores are on top along with
an overall gene score and p-value. Heat map shows relative gene expression (columns)
for sorted tumor cells with indicated KO (rows). Red is high expression and blue is low. I)
Growth of JB2 tumors with or without IFNA/GRKO after RT + anti-CTLA4 (n=5-10). Unless
indicated, error bars are S.E.M. of biological replicates.
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Figure 8: Tumor IFN signaling drives PDL1-independent resistance
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Figure 8: A) Survival after RT + anti-CTLA4 for mice with B16 tumors or tumors from B16
cells chronically treated with type I IFNB (B16b) (n=5-10). B) PDL1 expression on Res
499 cells after treatment with indicated doses of IFNL (µg/mL). C) Expression of PDL1 (an
ISG responsive to type I and II IFN signaling) on B16 and B16 cells with IFNGR knockout,
or D) B16 and B16 cells knocked-out for both IFNAR and IFNGR after treatment with IFNG
or IFNG and IFNB, respectively. E) Tumor volumes prior to the start of treatment for each
treatment schedule (Figure 2C). F) Tumor volumes after the indicated treatment schedule
with anti-CTLA4 + anti-PDL1 for mice with B16 tumors or B16 tumors with IFNGR
knockout or IFNGR and IFNAR knockout (IFNA/GRKO). G) Res 499 and Res 499 cells with
IFNGR knockout after treatment with IFNG H) Res 499 and Res 499 cells with IFNAR
knockout after treatment with IFNB. I) Res 499 and Res 499 cells with IFNAR and IFNGR
knockout after treatment with IFNG and IFNB. J) Expression of PDL1 and TNFRSF14 on
JB2 cells with IFNAR and IFNGR knockout after treatment with IFNB and IFNG. JB2 cells
were derived from Res 499 PDL1KO cells.
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Figure 9: STAT1 regulates a multigenic resistance program to ICB

Figure 9: A) Protein levels of STAT1 after two weeks of in vitro IFNG treatment of B16
cells followed by one-week washout (denoted B16γ). B) Principle components analysis of
differential open chromatin regions (OCRs) from ATAC-seq of melanoma cells sorted from
mice with the indicated tumors. C) Differential OCRs (rows) from B16γ vs. B16 (left) or
Res 499 vs. B16 (right) are shown for all tumors (columns) color-coded (bottom of heat
map) the same as the PCA plot. OCRs with predicted STAT1 binding sites are shown
(black lines beside heat maps). D) Normalized coverage from ATAC-seq reads at base
pair positions centered on STAT1 motifs. A fitted smoothing spline is shown for Res 499
or B16γ (dark red) or B16 (blue). E) Tumor volumes (day 15, split y-axis) or F) survival of
mice bearing Res 499 tumors with STAT1KO and/or PDL1KO after RT + anti-CTLA4 (n=1015). G) Correlation between Stat1 and the indicated genes from microarray analysis of
whole tumor lysates. Blue dots indicate p<0.05. H) Heat map of gene correlation matrix
with correlation value color-coded per the legend. I) Undirected ARACNE network graph
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using TCGA human melanoma expression data. Edges are weighted by mutual
information scores and nodes are color-coded by functional groups. J) Correlation
between STAT1 and other genes in the network under conditions where PDL1 expression
(x-axis) or CD8A expression (y-axis) is restricted to low/intermediate (left) or high (right)
expression values. Blue dots indicate p<0.05. K) Gene set analysis of TCIRs, TCIR
ligands, and ISGs. Individual gene scores are on top along with an overall gene score and
p-value. Heat map shows relative expression of genes (columns) for sorted tumor cells
with indicated KO (rows). Red is high expression and blue low.
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Figure 10: Biological processes and epigenomic and transcriptomic changes
regulated by tumor IFN signaling and STAT1

Figure 10: A) Expression of genes differentially expressed after IFNA/GRKO in Res 499
versus control in the indicated melanoma cells sorted from in vivo tumors by flow
cytometry. Also shown are Reactome gene sets with decreased (blue tones) or increased
(red tones) expression after individual and combined IFN receptor knockout. Size of circles
is proportional to number of genes, and circles are color-coded by p-value for statistical
significance as indicated in the legend. Thickness of lines is proportional to genes shared
between sets. B) Differential open chromatin regions by ATAC-seq with predicted STAT1
binding sites were determined by de novo motif search and matching discovered motifs
against the JASPAR database. Shown are representative top motifs, sequence logos, and
e-values for matches against STAT1 consensus (bottom). Only motifs with an e-value <
10–6 and a match to STAT1 ranking in the top 1% of transcription factor sites were
considered. C) Quantitative gene set analysis for B16γ vs. B16 (left) or Res 499 vs. Res
499 STAT1KO. Association between Stat1 expression and a previously described
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resistance gene signature109 derived from comparing resistant B16 melanoma tumors
(e.g., Res 499) with sensitive parental B16 tumors is analyzed for significance. The
individual gene scores are indicated on top along with an overall gene score and p-value.
Positive gene scores reflect positive correlation with Stat1. Bottom shows a heat map of
the relative expression of each gene (columns) for each tumor type (rows). Red is high
expression and blue is low. The dot plot on the right of the heat map indicates Stat1
expression levels for each tumor. D) Expression of PDL1 after treatment with IFNG on
Res 499 and Res 499 cells with STAT1 or STAT1 and PDL1 knockout.
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Figure 11: Blocking IFN-driven resistance interferes with multiple TCIR ligands
and improves response to ICB

Figure 11: A) Expression of TCIR ligands on Res 499 cells after in vitro treatment with
indicated type I or II IFN. B) Expression of TCIR ligands. Shown are representative
histograms and MFI values from biological replicates. Isotype controls are shown in
histograms on top. C) Gene set analysis of TCIRs, TCIR ligands, and ISGs. Individual
gene scores are on top along with an overall gene score and p-value. Heat map shows
relative expression of genes (columns) for sorted tumor cells with indicated KO (rows).
Red is high expression and blue low. D) Survival of mice bearing Res 499 tumors with
indicated KO after RT + anti-CTLA4 (n=20). E) Tumor growth and F) survival of mice with
Res 499 tumors treated with anti-CTLA4 + anti-PDL1 along with anti-LAG3 and/or antiTIM3 (n=5-15). For comparison with anti-CTLA4 + anti-PDL1, * p=0.02 and *** p<0.001.
For quadruple ICB vs. anti-CTLA4 + anti-PDL1 + anti-LAG3, p<0.01. G) Survival of mice
with Res 237 ICB-resistant breast cancer tumors treated with indicated ICB (n=5-10). H)
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Tumor growth and survival of mice bearing Res 499 tumors with or without IFNA/GRKO
after anti-CTLA4 + anti-PDL1 (n=5).
Figure 12: T cell inhibitory receptor ligands and identifying distinct exhausted T
cell populations involved in IFN-driven resistance

Figure 12: A) Expression of TNFRSF14 after treatment with IFNG on Res 499 cells with
TNFRSF14 and PDL1 knockout. B) Schematic of rationale and strategy for identifying
distinct T cell populations based on co-expression patterns of T cell inhibitory receptors
(TCIRs) in order to determine if severely exhausted T cells expressing high levels of
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multiple TCIRs (yellow) can preferentially expand when ligand expression on tumor cells
is disrupted by inhibiting tumor IFN signaling.
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Figure 13: Inhibiting IFN-driven resistance preferentially expands distinct
populations of TEX

Figure 13: A) Feature summary of nine populations (clusters) of CD44high CD8 peripheral
T cells identified using co-expression of six TCIRs. Heat map shows the scaled MFI (rows)
characterizing each cluster (columns). Clusters are additionally categorized (bottom
boxes) by TCIR and PD1 status (see legend). Baseline frequency of T cells in each cluster
compared to total splenic T cells (box plot) and frequency of Ki67high T cells is also shown
(black box indicates too few events). B) Co-expression of the six TCIRs on T cells
belonging to the PD1highTCIRhigh clusters Cl.5.2 and Cl.5.3. C) Percentage of CD8 TILs
that are Ki67+GzmB+ from Res 499 tumors with or without IFNA/GRKO grouped by antiCTLA4 + anti-PDL1 treatment (ICB). D) Distribution of Ki67+GzmB+ CD8 TILs in each
TCIR cluster, and E) percentage of Ki67+GzmB+ T cells in each TCIR cluster. F)
Representative contour plots of PD1 and Eomes expression (red), and Ki67 and GzmB
expression (blue), from CD8 TILs belonging to the PD1highTCIRhigh Cl.5.2 cluster. G)
Percentage of indicated peripheral PD1+ T cells over time. ICB was given at day 13. H)
Pie chart summarizing the average frequency of PD1+ CD8 peripheral T cells in each TCIR
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cluster. I) Day 20 percentage of Eomes+ Ki67+GzmB+ T cells in each TCIR cluster after
ICB. J) Representative contour plots and K) summary of Eomes and Ki67/GzmB status in
T cells from the indicated TCIR clusters at day 20. Ki67/GzmB analysis is restricted to the
Eomes+ population from each cluster. Unless indicated, error bars are S.E.M. of biological
replicates.
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Figure 14: T cell population identified by model-based clustering of T cell
inhibitory receptors

Figure 14: A) Co-expression of six T cell inhibitory receptors (TCIRs) for seven of the nine
TCIR clusters identified on splenic CD8 T cells by model-based clustering. See Figure
11H. B) Pie chart summarizing the average frequency of TRP2+ CD8 TILs in each TCIR
cluster for Res 499 and Res 499 IFNA/GRKO, or C) Res 499 and Res 499 STAT1KO.
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Figure 15: Disrupting IFN-driven resistance renders highly multi-ICB resistant
tumors sensitive to ICB monotherapy

Figure 15: A) Tumor growth of Res 499 tumors with the indicated IFN receptor KO after
anti-PD1 (left) or anti-CTLA (right) (n=5-10). *** p<0.001 for comparisons with Res 499.
For anti-CTLA4 (right), p=0.037 for IFNA/GRKO vs. IFNGRKO. B) Effect of IFN receptor KO
on survival of mice with Res 499 tumors or C) Res 237 ICB-resistant breast cancer tumors
treated with anti-CTLA4 (n=5-10). D) Contour plot of indicated TCIR ligands in Res 499
tumors from mice after treatment with a JAK inhibitor (JAKi). Red contours represent
melanoma cells and blue indicate CD45+ immune cells. Statistical summary from
biological replicates is shown on right. E) Treatment schedules for anti-CTLA4 and JAKi.
F) Tumor growth curves of Res 499 tumors from each treatment schedule (D8, n=10; D5,
n=7). G) Tumor growth of Res 237 breast cancer tumors treated with anti-CTLA4 and/or
JAKi for five days starting on day 10 (n=6). Unless indicated, error bars are S.E.M. of
biological replicates.
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Figure 16: Improved response after blocking tumor IFN signaling is CD8 T cell
dependent

Figure 16: A) Heat map of the relative RNA-seq expression of the indicated TCIR ligands
and ISGs from parental TSA breast cancer or Res 237 cells. Res 237 cells are from a TSA
tumor that relapsed after RT + anti-CTLA4. B) Mice with Res 499 IFNAR/IFNGR knockout
tumors were treated with anti-CTLA4 with or without anti-CD8 to deplete CD8 T cells.
Shown is a representative density plot of CD8 vs. CD4 T cell frequency in the tumor (box
indicates frequencies of CD8 T cells as a percentage of CD45+) and C) tumor growth
curves (n=5). D) Representative histogram and E) strip plot of in vivo mean fluorescence
intensity for MHC class I expression on melanoma cells from Res 499 tumors and Res
499 tumors with IFNAR/IFNGR knockout. F) Relative expression of MHC class I,
immunoproteosome subunits, TAP, IFN receptor, and IFN genes (rows) in human
melanoma and breast cancer cell lines (columns) from the Cancer Cell Line Encyclopedia
(CCLE). Data are normalized but not centered and expression is color-coded as indicated
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in the legends. White empty cells indicate absence of expression. G) Statistical summary
from biological replicates of TCIR ligands in Res 499 tumors from mice after 4 days of
treatment with a JAK inhibitory (JAKi) or control.
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Figure 17: ISGs associated with IFN-driven resistance can predict clinical
response to anti-PD1

Figure 17: .A random forest model for melanoma response/progression after anti-PD1
was developed using the number (Log10) of nsSNVs and the average mRNA expression
of IFIT1 and MX1 (IFIT1/MX1) for a cohort of 27 patients. Shown are A) overall error rates,
error rates for progression or response, and B) variable importance scores (greater than
0 is deemed significant) determined from out-of-bag (OOB) samples. Error bars represent
Monte Carlo standard deviations. C) Partial plots showing the adjusted effects of the
indicated variables on the probability of response. Red dashed lines are standard errors.
D) Predicted probabilities of response from OOB samples as a function of IFIT1/MX1 and
nsSNVs. Larger circle sizes represent higher probability (legend). Actual response (blue)
and progression (red) are denoted by circle color. Quadrants are divided by values from
partial plots approximating 50% probability of response. E) Association between
IFIT1/MX1 and nsSNVs with clinical response to anti-PD1 compared to other genes. Gene
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expression correlation is shown in the heat map (left). The frequency of bootstrap samples
that each variable was selected as significant for predicting response and its variable
importance are plotted (right). Grey dotted line for each axis is the upper 5% quantile. Top
variables are highlighted in blue and IDILS TCIR ligands in red. F) Partial plot representing
the adjusted effects of IFN-I on the probability of response. Red dashed lines are standard
errors. G) Model for IFN-driven resistance.
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CHAPTER 4: SUMMARY AND FUTURE DIRECTIONS

PD-L1 Mediated Resistance
The importance of the PD1/PD-L1 signaling axis in determining response to
immune checkpoint blockade has been well established. Here we show that tumor cells
expressing PD-L1 is the dominant mediator of resistance to anti-CTLA4+RT in mouse
models of both metastatic melanoma and breast cancer. PD-L1 expression by tumor cells
was more important in mediating resistance in our primary B16 and TSA tumors as
opposed to the relapsed resistant 499 and 237 tumors. In addition to expression of PDL1 by the tumor, high levels of PD-L1 were also observed in certain tumor infiltrating
lymphocytes, principally tumor associated macrophages200. In primary tumors, this PDL1 on immune cells seems less important in mediating resistance than in relapsed ICB
resistant tumor lines, although this needs to be studied more closely as a small effect
could be lost given the strong effect of knocking out PD-L1 in the tumor cells in these
parental tumor lines. One way to further evaluate the role of immune PD-L1 is by
implanting tumors into PD-L1 knockout mice161.
Macrophages are PD-L1 high in both parental and relapse tumors and depleting
them using anti-CSF1R in resistant tumors improves response to anti-CTLA4+RT.
However, it remains unclear if this benefit is through loss of a major expresser of PD-L1
in the tumor microenvironment, or through some other function of the macrophages. The
macrophages in these tumors were predominantly of the immunosuppressive M2
phenotype so they could have been inhibiting the immune response in a PD-L1
independent manner. Anti-CSF1R antibodies have previously been shown to be effective
in depleting tumor associated macrophages and increasing the CD8+/Treg ratio167,201. The
chemotherapeutic agent Trabectedin has also been shown to rapidly induce apoptosis
only in mononuclear phagocytes202. These offer exciting therapeutic options to potentially
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synergize with immune checkpoint blocking antibodies to improve the anti-tumor
response. Further study on how the macrophages are inhibiting the immune response by
utilizing conditional knockouts of PD-L1 in macrophages or adoptively transferring PD-L1
null macrophages into CD11b-DTR mice would be critical to understanding whether it is
PD-L1 expression or polarization that is modulating the immune response.
The importance of PD-L1 in both the tumor and immune compartments in
modulating resistance was also confirmed in our clinical trial of anti-CTLA4+RT. Patients
who had high PD-L1 staining on their tumor, macrophages, or both responded poorly to
treatment. Similar results have been reported by other groups, with high PD-L1 staining
predicting worse response to anti-CTLA4 monotherapy91. Unlike in our models, it is less
well defined whether tumor or immune PD-L1 is more important in predicting response in
patients. One of the main issues with comparing results across trials is that there is no
unified standard for defining PD-L1 staining intensity, making it difficult to compare results
across trials. Additionally, macrophages are generally not subset with additional markers
making it challenging to know what role macrophage polarization plays in ICB resistance,
regardless of whether the macrophages are PD-L1 positive or not. While PD-L1 seems
to be a critical mediator of resistance especially to anti-CTLA4, there is also PD-L1
independent resistance as illustrated by the patients on our clinical trial of anti-CTLA4+RT
who progressed and went on to further progress on anti-PD-1 regardless of the PD-L1
status of their tumor. Additionally, the differential effect of knocking out PD-L1 in primary
versus relapse tumors also suggests that over the course of an immune response tumor
cells may acquire additional PD-L1 independent resistant mechanisms consistent with the
idea of adaptive immunity168,200.

STAT1/Interferon Mediated Changes in Parental and Relapse Cell Lines
While PD-L1 signaling is one of the most well-studied resistance mechanisms in
immunotherapy, and one of the dominant mediators of resistance in our model, our results
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also implicate additional PD-L1 independent resistance mechanisms.

499 PD-L1

knockout tumors that relapsed over 40 days after initial treatment with anti-CTLA4+RT
(JB2) were completely resistant to treatment when transplanted into naïve mice. The loss
of neo-antigens through immunoediting is one possible PD-L1 independent resistance
mechanism, but our resistant cell lines have lost very few predicted neo-antigens
compared to their respective parental cell lines by exome-seq.

Interferon signaling

through STAT1 drives PD-L1 and other inhibitory pathways in multiple cell types109,145, and
knocking out interferon signaling in JB2s dramatically resensitized them to treatment,
suggesting interferon driven resistance is the major PD-L1 independent resistance
mechanism in our model. In our mouse models of primary and relapsed melanoma and
breast cancer both type I and type II interferons are capable of inducing PD-L1 expression
as well as the expression of multiple other CD8+ T cell inhibitory ligands200.
Despite these commonalities between the parental and relapsed cell lines,
knocking out STAT1 or the interferon receptors had divergent effects in our parental
versus relapsed cell lines. Loss of STAT1 led to worse response to anti-CTLA4+RT or
anti-PD1 monotherapy in parental B16 or TSA but improved response in the 499 and 237
relapsed lines.

One reason for this differential response is likely chronic interferon

exposure during the relapse process. After B16 tumors are treated with anti-CTLA4+RT
interferon gamma is produced in high enough quantities to be detected in the peripheral
blood by ELISA. In vitro treatment of B16 cells with low levels of interferon gamma for 3
weeks was sufficient to render them resistant to anti-CTLA4+RT when they were injected
into mice.

Interferon signaling through STAT1 has also been shown to orchestrate

chromatin remodeling203; we observe changes in chromatin openness at STAT1 binding
sites in 499 compared to B16 by ATAC-seq suggesting these changes could be promoting
resistance. One outstanding question is how these chromatin changes correlate with
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transcriptional changes that mediate the differential response to immune checkpoint
blockade between primary and relapsed tumors.
Clinical trials taking pre- and post-treatment biopsies from patients receiving
immune checkpoint blockade have focused on transcriptomic changes or antigenic shifts
through RNA-seq or Exome-seq.

There is little available information on possible

epigenetic changes that could be occurring over the course of treatment and exposure to
interferon or other signals that could lead to chromatin remodeling. These epigenetic
changes could prove important in predicting response especially in patients with a large
immune infiltrate whose tumors could have already been chronically exposed to interferon
even

before

treatment.

Identifying

what

chromatin

changes

correlate

with

response/resistance to immune checkpoint blockade in paired pre-clinical models of
parental and relapsed tumors is an important first step. One potential way to combat these
epigenetic changes would be through inhibitors that alter how proteins interact with
chromatin such as JQ1204. Blocking transcription through the newly open STAT1 binding
sites in the relapsed tumors with a drug such as JQ1 could potentially reverse resistance
and should be evaluated as a possible adjuvant therapy in our relapsed models.

Interferon Signaling Regulates Response in Resistant Tumors
Inhibiting interferon signaling by knocking out either the type I, type II, or both
interferon receptors dramatically resensitized resistant tumors to single agent immune
checkpoint blockade.

This improved response was accompanied by a significant

expansion of tumor reactive CD8+ T cells that had high expression of multiple inhibitory
ligands are generally considered terminally exhausted (Figure 18).

In addition to a

numeric expansion, these inhibitory ligand high T cells also had increased levels of
Granzyme B and Ki67 suggesting that they were reinvigorated. These findings suggest
the ability to uncouple exhaustion from response by targeting inhibitory ligands in the
tumor en masse through blocking interferon signaling. As knocking out the interferon
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receptors in patients would be challenging, we also showed that administering a clinically
available JAK inhibitor to mice with wild-type tumors also dramatically resensitized them
to single agent ICB. Translating this finding into patients requires identifying the proper
timing of ICB and JAK inhibitor administration as inhibiting interferon too early can
completely abrogate the immune response183. In mice, multiple deeply exhausted T cell
populations expand after ICB in tumors without interferon signaling. Identifying which
populations are most important for response by sorting them out of tumors and doing in
vitro functional assays will be important in identifying biomarkers that the combination of
JAKi and ICB is working in patients.
We have identified more than five known inhibitory ligands regulated by interferon
signaling in our mouse models. The role of PD-L1 as one of the primary drivers of
resistance has already been established in our model but further work is needed to isolate
the contribution of the other ligands. Individual knockouts or overexpression of each of
these ligands is important to identify which interferon driven inhibitory ligands are
important for predicting response to ICB. Paired with any epigenetic markers of resistance
from the ATAC-seq, looking for expression of the identified ligands in patient tumors would
enable more accurate identification of patients who would benefit from the JAK inhibitor.
Our preliminary work using either anti-CTLA4 or anti-PD1 monotherapy in IFNAR
or IFNGR knockout tumors has identified differences in response to each ICB in each
IFNR KO tumor. Consistent with prior observations, type I and type II interferons have
overlapping and distinct effects on the cells and these effects appear to pertain to ICB
response as well.

Deconvoluting proteomic, transcriptomic, or epigenetic signatures

associated with exposure to type I, type II, or both types of interferon will likely be important
in choosing which ICB to combine with the JAK inhibitor, as well as possibly more specific
inhibitors blocking either type I or type II interferon signaling. The differential regulation of
ISGs by type I and type II interferon may also differentially affect the T cell response or
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implicate additional immune subtypes in the response. For example, type II IFN drives
class I MHC expression in our models and therefore blocking IFNGR could lead to NK cell
involvement through missing self. Additionally, many T cell inhibitory receptors are also
expressed on other immune subtypes such as NK cells and loss of the inhibitory ligands
on the tumors could allow these cells to participate in the immune response as well.
Identifying the relative contributions of type I and type II interferon signaling to different
types of ICB resistance is an important step in identifying which patients will benefit from
a JAKi or other methods of blocking interferon signaling in the tumor.
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Figures
Figure 18: Model of Interferon-Driven Resistance to Immune Checkpoint Blockade
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CHAPTER 5: MATERIALS AND METHODS

Experimental Model and Subject Details
Mice
All animal experiments were performed according to protocols approved by the
Institutional Animal Care and Use Committee of the University of Pennsylvania. Five to
seven week old female C57BL/6 (Stock# 027), BALB/c (Stock# 028), were obtained from
Charles River Laboratory. Five to seven week old female C57BL/6 (Stock# 000664) and
IFNy KO (B6.129S7-Ifngtm1Ts/J –Stock# 002287) were obtained from Jackson
Laboratory (Bar Harbor, ME). Mice were maintained under pathogen-free conditions.
Human
The clinical trial of RT and anti-CTLA4 for metastatic melanoma patients
(NCT01497808) has been described in detail109. The study protocol was approved by the
University of Pennsylvania institutional review board. All participating patients provided
written informed consent.
Cell Lines
B16-F10 melanoma cells, TSA breast cancer cells, and resistant sublines were
derived and cultured as previously described109.
Method Details
Immunohistochemistry for PDL1
Details on PDL1 staining of formalin-fixed, paraffin-embedded tumors collected at
the time of surgical resection or from biopsy have been described109. In brief, intensity of
staining on a 0-3+ scale, the percent positive staining on tumor cells or macrophages
(identified by H&E and morphological features), and the cellular pattern (membrane vs
cytoplasm) were independently analyzed by two pathologists.
CRISPR gene targeting
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Gene targeting by CRISPR/Cas9 was accomplished by co-transfection of a Cas9
plasmid (Addgene, 41815), the guide sequence (selected using ZiFit Targeter) cloned into
the gBlock plasmid, and a plasmid with the puromycin selection marker. Gene blocks used
contain a 20 bp target size (N), U6 promoter, gRNA scaffold, and termination signal. The
sequence and sequences for each guide used are listed in Supplemental Table 1.
Successful targeting of the gene(s) of interest was determined by treating cells with and
without 100 ng/mL of interferon (IFN)-gamma (PeproTech), 1000 units/mL IFN-beta (PBL
Assay Science), or both depending on the target gene, and examining PDL1 and
TNFRSF14 surface expression by flow cytometry. Knockout cells were sorted from a bulk
knockout population using Fluorescence Activated Cell Sorting (FACS) on the Aria (BD)
or FACSJazz (BD) to maintain the diversity of the parent cells.
In vivo mouse studies
Tumor injection and treatment schedule were done as previously described109.
Blocking antibodies were given on days 5, 8, and 11 unless otherwise specified. Anti-CD8
was given on days -2, 0, 4, 8, 12, and 16. Anti-CSF1R was given every 3 days starting on
day 5. For in vivo experiments CTLA4 (9H10), PDL1 (10F.9G2), PD1 (Merck mDX400),
CD8 (2.43), and Lag3 (C9B7W), and were all administered intraperitoneally at 200
ug/dose. TIM3 (BE0115) was given at 250 ug/dose, and CSF1R (AFS98) was given at 1
mg/dose. Ruxolitinib was administered intraperitoneally at 60 mg/kg. Isotype controls were
used to confirm the lack of non-specific effects and a similar response and survival to
untreated mice.
Flow cytometry
Spleen and tumor were harvested at day 15 post tumor implantation. Single-cell
suspensions were prepared and red blood cells were lysed using ACK Lysis Buffer (Life
Technologies). Live/dead cell discrimination was performed using Live/Dead Fixable Aqua
Dead Cell Stain Kit (Life Technologies). Cell surface staining was done for 30 min at 4
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degrees. TRP2 and Ova tetramer (MBL International) staining was done at 37 degrees for
90 minutes and then surface antibody staining was performed. Intracellular staining was
done using a fixation/permeabilization kit (eBioscience). All data acquisition was done
using an LSR II (BD) or FACSCalibur (BD) and analyzed using FlowJo software (TreeStar)
or the FlowCore package in the R language and environment for statistical computing.
ELISA
Mice were treated with anti-CTLA4 on days 5, 8, 11 and 20 Gy RT to the right
tumor on day 8. Peripheral blood was collected on days 3, 6, 10, 14, and 17, and plasma
was centrifuged at 850 x g for 10 minutes. Supernatants were frozen in aliquots and
subsequently analyzed by ELISA for mouse IFN alpha (Affymetrix), beta (PBL Assay
Science), and gamma (Life Technologies) according to manufacturer’s instructions.
RNA-Seq of sorted mouse tumors
Mice were injected with tumors as previously described. On day 15 tumors were
harvested, red blood cell lysis was performed, and a single cell suspension was created.
Tumor cells were stained with Live/Dead Aqua and CD45. Samples were sorted on an
Aria (BD) by gating on live, CD45 negative cells. Total RNA was isolated and purified from
the cells using Isol-RNA Lysis Reagent (Fisher) and treated with DNase I (Fisher). RNAseq libraries were prepared using the TrueSeq Stranded Total RNA Library Prep Kit
(Illumina) and sequenced on Illumina HiSeq 2500 with 100 base paired end reads.
ATAC-Seq of sorted mouse tumors
ATAC-seq libraries were prepared as described previously205. Approximately
200,000 sorted tumor cells were used for each library using the same sort methodology
as RNA-seq. Libraries were sequenced on Illumina HiSeq 2500 with 100 base pair end
reads.
Exome-Seq of mouse melanoma cell lines
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Genomic DNA was isolated and purified from tumor cell lines in vitro using Purelink
Genomic DNA Kit (Fisher) and exome libraries were prepared using the SureSelectQXT
Kit (Agilent) with SureSelectXT Mouse All Exon bait. Libraries were sequenced on an
Illumina HiSeq 2500 with 100 base paired end reads. Reads were trimmed with
AgilentReadTrimmer (Agilent) and then aligned to GRCm38 reference genome using
BWA v0.7.12 (Li and Durbin, 2009) with the bwa-mem algorithm. Aligned reads were
deduplicated with Picard Tools and processed using GATK v3.3.0 (McKenna et al., 2010).
Variants were called using the GATK Unified Genotyper and hard filtered with filters
according to GATK best practices recommendations (Van der Auwera et al., 2013;
DePristo et al., 2011): QD < 2.0; MQ < 40, FS > 60, MQRankSum < -12.5 and
ReadPosRankSum < -8. Variants were annotated using the VariantAnnotation R package
version 1.16.4 (Obenchain et al., 2014). Losses of heterozygosity (LOH) mutations were
defined as an allele frequency of less than 0.02 in the Res 499 cell line but higher than
0.02 in the parental B16 cell line. Variants found in transcripts with no evidence of RNA
expression by RNA-seq were filtered out. Eight to 10-mer peptides surrounding each nonsynonymous mutation were extracted and their H-2Kb and H-2Db MHC-I binding affinities
were predicted using IEDB (http://www.iedb.org) using the ANN algorithm. Peptides were
then assessed for a predicted affinity of 500 nM or less and 50 nM or less.
Quantification and Statistical Analysis
Analysis of tumor volume, growth curves, and survival curves
Mice were randomly assigned a treatment group and tumor volume determined by
caliper measurements. Differences in survival were determined for each group by the
Kaplan-Meier method and the overall p-value was calculated by the log-rank test using
the survival R package version 2.38-3. For mouse studies, an event was defined as death
or when tumor burden reached a pre-specified size to minimize morbidity. A mixed effect
linear model using the lmerTest R package version 2.0 was used to determine differences
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in growth curves. The significance of all two-way comparisons was determined by twosample, two-tailed t-test. For non-parametric data, a Wilcoxon or Mann-Whitney test was
used. Significance of tumor growth was determined by a mixed effect linear model. Simple
correlation between variables was done using a Spearman correlation.
Analysis of RNA-seq of sorted mouse tumors
Reads were trimmed first using cutadapt v1.9206 with parameters -q 10 -m 30 -O
4. Trimmed reads that were aligned to rRNAs sequences were removed and the remaining
sequences were aligned to the GRCm38 reference genome using STAR v2.4.0k207 with
parameters

--outFilterMultimapNmax

100

--outFilterMismatchNmax

999

--

outFilterMismatchNoverLmax 0.06. Primary aligned reads were counted against
GENCODE annotation vM4 (Mudge and Harrow, 2015) using Subread v1.4.6208 with
parameters -s 2 -minReadOverlap 10. The DESeq2 R package version 1.10209 was used
for differential gene expression analysis.
Analysis of ATAC-seq of sorted mouse tumors
Reads were trimmed using cutadapt v1.9 with parameters -m 30 -O 4, and mapped
to the reference genome using bowtie2 v2.2.4210 with parameters --fr --no-mixed --nodiscordant --X 2000. Reads were then deduplicated with Picard Tools v1.140. Secondary
alignment and low quality reads (mapQ <= 10) were filtered out and all reads aligning to
the plus strand were offset by +4 bp, and all reads aligning to the minue strand were offset
−5 bp205. Peaks were called using MACS2 v2.1.0 (Feng et al., 2012) with parameters -f
BAMPE --no-model and FDR cutoff 0.01. Regions overlapping with the ENCODE
“blacklist” were removed. The DiffBind R package version 1.16 (Ross-innes et al., 2012)
was used for differential binding analysis with a false discovery rate of 0.10. The rGADEM
R package version 2.18 was used for motif discovery. Discovered motifs were then
matched against the JASPAR database. Only motifs with an e-value < 10–6 and had a
STAT1 binding site ranking in the top 1% of all transcription factors examined were kept.
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For DNA footprinting, open chromatin regions (OCRs) were scanned for transcription
factor footprinting using Wellington (Piper et al., 2013) with p-value cutoff -10. Identified
footprinted regions were then extended 5bp on each side and scanned for STAT1 motifs
using FIMO (Grant et al., 2011) with default settings and Position Frequency Matrices
(PFMs) from the JASPAR database. Mapped reads from replicates were merged and the
transposon cutting positions (5’ end of mapped reads) were counted around the identified
motifs. Counts were normalized to the total insertion sites in OCRs.
Analysis of mouse and human genes associated with STAT1
Using either mouse microarray data for Res 499 and B16 tumors or patient
melanoma data from TCGA, the strength of the correlation between STAT1 and genes
from a manually curated gene list that included previously described cancer-associated
ISGs (IFI44, IFIT1, IFIT3, ISG15, MX1, OAS1)140, T cell inhibitory receptors (TCIRs), TCIR
ligands, and other IFN regulated immune suppressive mediators such as IDO1 was
determined by calculating a Spearman correlation coefficient along with the associated
two-sided p-value. For the mouse data, microarray expression values from Res 499 and
B16 tumors were examined separately and the correlation between STAT1 and each gene
compared between these groups. For TCGA human melanoma data, additional genes
were added to the gene list as a surrogate for T cell infiltration, including CD8A, PRF1,
and GzmA. In order to analyze which genes most strongly influence STAT1, a gene
network was constructed using ARACNE, as implemented in the minet R package version
3.28211. Using the resulting mutual information matrix, an undirected graph was
constructed with edges weighted by the mutual information scores. Based on the network
findings, CD8A and PDL1 mRNA expression values were divided into q-quantiles, where
q = 6, in order to examine how perturbing each of these genes, which formed strong
connections with STAT1, would influence the correlation between STAT1 and other genes
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in the network. Specifically, within each quantile for CD8A or PDL1, the correlation
coefficients and p-values between STAT1 and other genes in the network were compared.
Gene set enrichment analysis
To test whether gene sets were enriched in response to different conditions, we
utilized Gene Set Analysis as implemented in the GSA R package version 1.03212 or the
piano R package. For GSA, the “maxmean” test statistic was used to test enrichment using
a two-class comparison when comparing groups or quantitative analysis for continuous
variables. All p-values and false discovery rates were based on 500-1000 permutations.
For restandardization, a method that combines randomization and permutation to correct
permutation values of the test statistic and to take into account the overall distribution of
individual test statistics, the entire data set was used rather than only the genes in the
gene sets tested. Gene signatures examined included a manually curated list of TCIRs,
TCIR ligands, and ISG (Figure 3H) and the upregulated genes from a resistance signature
for radiation and anti-CTLA4109. For the piano implementation, Reactome gene sets were
downloaded

from

the

Molecular

Signatures

Database

v5.1

(http://software.broadinstitute.org/gsea/msigdb).
Random forest for classification and survival analysis
Random forest (RF) for classification, regression, and survival analysis is a
multivariable non-parametric ensemble partitioning tree method that can be used to model
the effect of all interactions between genes on a response variable213. Each model was
constructed using approximately two-thirds of randomly selected samples and crossvalidated on the one-third of the samples left out of the model building process (out-of-bag
samples). After many iterations, results of all models were averaged to provide unbiased
estimates of predicted values, error rates, and measures of variable importance.
Performance of an RF model was measured by the misclassification error rate for
classification and by a concordance index (one minus the error rate) for survival. For each
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gene, an importance score was determined, which measures the contribution of the
variable to the error rate (higher scores are more predictive). We used the
randomForestSRC package version 2.0.7189 and the following parameters: 1000 trees,
node size of 2, and mtry values equal to the number of variables in the model. The default
splitting rule was used for classification and the log-rank slitting rule was used for survival
analysis. For small sample sizes, 500 Monte Carlo replications were used and the results
averaged. All predicted values, error rates, and importance scores were based on crossvalidation using out-of-bag samples to provide unbiased estimates. To examine the effect
of sampling error on variable selection, 1000 bootstrap samples were utilized and variable
selection was performed using the minimal depth statistic189.
T cell inhibitory receptor expression analysis
To determine the patterns of T cell inhibitory receptor expression, splenic T cells
were isolated from mice bearing Res 499 or Res 499 IFNAR/IFNGR knockout tumors and
processed for flow cytometry. Fluorescence intensity data were analyzed using the
flowCore R package version 1.36.3 and transformed using the logicle method. After
excluding debris, dead cells, doublets, and non-T cell populations using a dump channel,
the CD44high CD8 T cell population was identified. From this population, T cells that were
negative for all T cell inhibitory receptors (TCIRs) examined (PD1, LAG3, 2B4, TIGIT,
TIM3, CD160) were excluded. From the remaining CD44high CD8 T cells, the expression
of the TCIRs was used as features for model-based clustering as implemented in the
mclust R package version 5.1. An ellipsoidal distribution, variable shape, variable
orientation, and variable volume were used as model parameters. An aggregate data
matrix from random sampling of 1000 to 5000 events from each sample was used for
clustering analysis. The number of initial clusters was estimated based on the “elbow”
from the Bayesian Information Criterion as a function of cluster number. Resulting clusters
were then inspected and the within cluster sum of squares calculated. Cluster(s) with the
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highest within cluster sum of squares and confirmed to be a persistently mixed population
by inspection of scatter plots for all pair-wise combinations was then re-clustered using
the same steps. This procedure resulted in nine TCIR clusters. Using cluster membership
as class definitions, a random forest (RF) based classifier was developed using the same
aggregate data matrix. This RF classifier had an out-of-bag error rate of less than 5% and
was used to assign CD44high CD8 T cells from a new sample from either the periphery
or the tumor to one of the nine TCIR clusters.
Data and Software Availability
Software
PRISM

was

used

for

some

basic

statistical

analysis

and

plotting

(http://www.graphpad.com), while the R language and environment for statistical
computing and graphics (https://www.r-project.org) was used for the majority of the
statistical and bioinformatics analysis. The R packages used for various analysis
described

in

the

methods

(https://www.bioconductor.org)

were

and/or

obtained
from

from
CRAN

Bioconductor
(https://cran.r-

project.org/web/packages/). Additional software and packages for processing, alignment,
and analysis of sequencing data include:
cutadapt (https://pypi.python.org/pypi/cutadapt)
Subread (http://subread.sourceforge.net)
bowtie2 (http://bowtie-bio.sourceforge.net/bowtie2/index.shtml)
Picard Tools (https://broadinstitute.github.io/picard/)
MACS2 (https://pypi.python.org/pypi/MACS2)
Wellington (https://pypi.python.org/pypi/pyDNase/0.2.3)
FIMO (http://meme-suite.org/doc/fimo.html)

Data Resources
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The RNA and ATAC sequencing data has been deposited at the GEO
(http://www.ncbi.nlm.nih.gov/geo) under the accession number GSE83850.
Mouse microarray and human gene expression data
Normalized Affymetrix GeneChip Mouse Gene ST Array data for B16 and Res 499
tumors have been previously described109 and were used to examine expression of
interferon and interferon receptor gene transcripts. Z-scores for mRNA expression data
for melanoma patients from The Cancer Genome Atlas (TCGA) were obtained from
cBioPortal (http://www.cbioportal.org). RMA normalized gene expression data for human
melanoma and breast cancer cell lines were obtained from the Cancer Cell Line
Encyclopedia (http://www.broadinstitute.org/ccle/home). Normalized transcriptomic data,
summarized exome analysis, and annotations for human melanoma patients treated with
anti-PD1

were

previously

described142

and

downloaded

from

the

GEO

(http://www.ncbi.nlm.nih.gov/geo), accession GSE78220. When multiple probes existed
for the same gene, the probe values were averaged.

Additional Resources
REAGENT or RESOURCE
Antibodies

SOURCE

IDENTIFIER

H-2 Kb TRP2 Tetramer

MBL International

T03015

Anti-mouse CD8

MBL International

D271-4

Anti-mouse TIGIT

BD Biosciences

565270

Anti-mouse Ki67

BD Biosciences

563757

Anti-mouse LAG-3

BioLegend

125219

Anti-mouse 2B4

Life Technologies

553305

Anti-mouse/human CD44

BioLegend

103031

Anti-mouse TIM-3

BioLegend

119703

Anti-mouse/human Granzyme B

Life Technologies

GRB17

Anti-mouse PD1

BioLegend

109110

94

Anti-mouse Eomes

eBioscience

50-4875

Anti-mouse CD45.2

BioLegend

109822

Anti-mouse CD8a

BioLegend

100713

Anti-mouse CD160

BioLegend

143008

Anti-mouse B220

eBioscience

47-0452

Anti-mouse CD4

eBioscience

47-0042

Anti-mouse NK1.1

eBioscience

47-5941

Anti-mouse CD3

BioLegend

100229

Anti-mouse MHCII

BioLegend

107631

Live/Dead Aqua

Life Technologies

L34957

Anti-mouse CD80

BioLegend

104731

Anti-mouse CD86

BioLegend

105043

Anti-mouse CD112

Abcam

EPR6717

Anti-mouse PD-L1

eBioscience

46-5982

Anti-mouse Galectin9

BioLegend

136103

Anti-mouse CD155

BioLegend

131511

Anti-mouse HVEM

BioLegend

136305

Anti-mouse CD48

BioLegend

103431

Anti-mouse F4/80

BioLegend

123114

Anti-mouse CTLA-4

BioXCell

BE0131

Anti-mouse PD-L1

BioXCell

BE0101

Anti-mouse PD-1

Merck

mDX400

Ruxolitinib

LC Laboratories

R-6688

Mouse interferon beta, carrier-free

PBL Assay Science

12401-1

Recombinant murine interferon gamma

PeproTech

315-05

ThermoFisher

KMC4022

Chemicals, Peptides, and Recombinant Proteins

Critical Commercial Assays
IFN gamma ELISA Kit

Scientific
TruSeq Stranded Total RNA Library Prep Kit

Illumina

RS-122-2303

Nextera DNA sample prep

Illumina

FC-121-1030
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Antibody Concentration Kit

Abcam

Ab102778

FITC Conjugation Kit

Abcam

Ab102884

GEO

GSE83850

Mouse: B16-F10

ATCC

ATCC CRL-6475

Mouse: TSA

Laboratory

Deposited Data
RNA and ATAC sequencing

Experimental Models: Cell Lines

of PMID: 19706802

Sandra Demaria
Mouse: 499, 237, 499 PDL1 KO

Laboratory of Andy
Minn

Mouse: JB2, all other CRISPR KO cell lines

This paper

N/A

Mouse: C57BL/6

Charles River

027

Mouse: BALB/c

Charles River

028

Mouse: C57BL/6J

The

Experimental Models: Organisms/Strains

Jackson 00664

Laboratory
Mouse: B6.129S7-Ifngtm1Ts/J

The

Jackson 002287

Laboratory

Recombinant DNA
N/A

Sequence-Based Reagents
See Table S1 for CRISPR/Cas9 gRNA Sequences:

This paper

Software and Algorithms

R language and environment for statistical
computing and graphics
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https://www.rproject.org

Table S1

Bioconductor and packages

https://www.biocon
ductor.org

CRAN

https://cran.rproject.org/web/pa
ckages/

cutadapt

https://pypi.python.
org/pypi/cutadapt

STAR

https://github.com/
alexdobin/STAR/re
leases

Subread

http://subread.sour
ceforge.net

bowtie2

http://bowtiebio.sourceforge.ne
t/bowtie2/index.sht
ml

Picard Tools

https://broadinstitut
e.github.io/picard/

MACS2

https://pypi.python.o
rg/pypi/MACS2

Wellington

https://pypi.python.
org/pypi/pyDNase/
0.2.3

FIMO

http://memesuite.org/doc/fimo.
html
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CRISPR Guide Information
Sequence for gBlock containing 20 bp target size (N), U6 promoter, gRNA scaffold
and a termination signal.

gBlock

TGTACAAAAAAGCAGGCTTTAAAGGAACCAATTCAGTCGACTGGATCCG
GTACCAAGGTCGGGCAGGAAGAGGGCCTATTTCCCATGATTCCTTCATA
TTTGCATATACGATACAAGGCTGTTAGAGAGATAATTAGAATTAATTTGAC
TGTAAACACAAAGATATTAGTACAAAATACGTGACGTAGAAAGTAATAATT
TCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAAATGGACTATCATAT
GCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCTTGTG
GAAAGGACGAAACACCGNNNNNNNNNNNNNNNNNNNGTTTTAGAGCTA
GAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGG
CACCGAGTCGGTGCTTTTTTTCTAGACCCAGCTTTCTTGTACAAAGTTGG
CATTA

PDL1 g1

GCTCCAAAGGACTTGTACGG

PDL1 g2

ACTTGTACGTGGTGGAGTAG

PDL1 g3

TATGGCAGCAACGTCACGAG

STAT1 g1

GACTCCAAGTTCCTGGAGCG

STAT1 g2

CAGCTGGACTCCAAGTTCCG

STAT1 g3

TACGATGACAGTTTCCCCAG

HVEM g1

GGGTCGGCACCCTGGAGCCG

HVEM g2

CCTGAAGGTGTTGTCTGTAG

HVEM g3

TCTGTAGGGGCCTGGCTCCG

IFNAR g1

GGCGCGGCGGCCCTGGTGCG

IFNAR g2

CTGGTGGCCGGGGCGCCTTG

IFNGR g1

CCCGCAGGCGGCAGCTGGCG

IFNGR g2

GTCCTGATGCTGTCTGCGAG
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